投資 – ページ 16 – ワールドソルーションズLLC

U.S.A. アメリカ Vol.115（Indiana インディアナ州 Vol.2: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Indiana Vol.8 (corporations: Eli Lilly)

追加

COVID-19 SETBACKS: As hospitalizations climb in America – with a field hospital set to open in Wisconsin Wednesday – Johnson & Johnson and Eli Lilly are reporting setbacks on vaccine and antibody treatment trials, respectively. @sramosABC reports. https://t.co/GnnUv1Mazk pic.twitter.com/PpPYNsCWBP

— World News Tonight (@ABCWorldNews) October 14, 2020

Eli Lilly says it is pausing the trial of its coronavirus antibody treatment because of a safety concern https://t.co/1H99MmaraN Johnson & Johnson said on Monday it would pause its COVID-19 vaccine trial due to an unexplained illness https://t.co/fTnt6q7uwa pic.twitter.com/EQzoQcBoX0

— Reuters (@Reuters) October 13, 2020

“This is an indication that the system is working as it was designed to work to protect human subjects in clinical trials,” said Lawrence Gostin, a public health and legal expert at Georgetown and Johns Hopkins universities. https://t.co/pZkPkzRSt2

— Statesman Journal (@Salem_Statesman) October 14, 2020

Coronavirus update: Regeneron, Eli Lilly seek FDA approval of antibodies, boosted by Trump's bout with COVID https://t.co/OdhsKigIwu by @AnjKhem pic.twitter.com/m05Ue3NYJi

— Yahoo Finance (@YahooFinance) October 11, 2020

Coronavirus update: Eli Lilly eyes emergency use for antibodies; Trump fumes over FDA vaccine guidelines https://t.co/g84f6tDmOI by @AnjKhem pic.twitter.com/ykVbjTX68x

— Yahoo Finance (@YahooFinance) October 8, 2020

The US pharmaceutical firm Eli Lilly announced it had applied for an emergency use authorization (EUA) for a lab-produced antibody treatment against Covid-19, after early trial results showed it reduced viral load, symptoms and hospitalization rates https://t.co/lOiibBnhLm

— AFP news agency (@AFP) October 7, 2020

ICYMI: @BillGates explains how the Bill & Melinda Gates Foundation has been “working with the companies doing antibodies” research for Covid-19 treatment. #MTP

Gates: “We’re partnered with Eli Lilly, who with Regeneron, has been the fastest to get these antibodies ready.” pic.twitter.com/JjAHoYGZPf

— Meet the Press (@MeetThePress) October 12, 2020

Project warp speed dropped the ball on antibodies. Was a mistake to focus mostly on vaccines and not enough on scaling up antibodies production (beyond what Regeneron and Eli Lilly can do) https://t.co/33zCOgkzMy

— avidresearch (@avidresearch) October 12, 2020

Monoclonal Antibodies for #SARSCoV2 #COVID19
(Regeneron, Eli Lilly, and Prometheus)
Great report by @apoorva_nyc

[1] Monoclonal antibodies are artificially synthesized copies of the most effective antibodies produced naturally by patients. https://t.co/cIh0ylmaIo

— Rajeev Chitguppi MDS (@chitguppi) October 13, 2020

Based on what's in the press release, these are impressive data and will surely lead to EUA for antibodies.

Reduction in ER or hospital visits from 5.8% in placebo to 0.9%. This is first demonstrated efficacy on clinical endpoints.https://t.co/HG4aWLS7nI via @statnews

— Walid Gellad, MD MPH (@walidgellad) October 7, 2020

Was it a blessing or a curse for Eli Lilly & Co. that President Donald Trump was treated with coronavirus antibodies made by rival Regeneron? https://t.co/ZS9tEO0lgv

— Bloomberg (@business) October 13, 2020

Eli Lilly has paused its monoclonal antibodies clinical trial after a participant got sick.

"They can produce infusion reactions and may be associated with everything from mild fever or rashes to anaphylactic shock,” @angie_rasmussen told me https://t.co/cXMPK37b0l @newrepublic

— Melody Schreiber (@m_scribe) October 13, 2020

An update on the Eli Lilly pause: researchers found a difference in the "clinical status" between people getting the placebo and the antibodies. We don't yet know what that means. But it's possible hospitalized patients may not benefit from the treatment.https://t.co/77byH7seUF

— Katherine J. Wu, Ph.D. (@KatherineJWu) October 14, 2020

Eli Lilly halts COVID-19 antibody treatment trial over 'safety concern' https://t.co/bbb5EJsIZm via @nypost
President Trump was given an experimental cocktail of manufactured antibodies to help in his bout with the virus and has since called his treatment a “miracle” and “cure”

— Muhammad Zafrullah (@mzafrullah) October 13, 2020

A Regeneron spokesman said its manufacturer "expects to begin delivering product in the first quarter of 2021," and that another company pursuing an EUA for monoclonal antibodies is working to meet demand. That company, Eli Lilly, just paused its trial. https://t.co/tPG7mTo5gO

— Michael Wilner (@mawilner) October 13, 2020

Eli Lilly press release* suggests monoclonal antibodies reduce COVID symptoms and hospital visits

*ie data not yet peer reviewed https://t.co/iP0431dweT

— Tim Lahey (@TimLaheyMD) October 7, 2020

Earlier today, I predicted that Trump would be treated with one of the experimental antibody treatments for #COVID19 (either from Regeneron or Eli Lilly). These work by providing “passive immunity,” similar to convalescent plasma, but are manufactured.https://t.co/ZnPrctsgMr

— Dena Grayson, MD, PhD (@DrDenaGrayson) October 2, 2020

IU and Eli Lilly are working together on potential therapies that range from using plasma from infected people to treat those hospitalized to developing drugs with antibodies to fight coronavirus. https://t.co/TxUYjQKJq3

— IndyStar (@indystar) May 6, 2020

ツイッター検索で上記製薬会社及び Japan や日本の5製薬会社各社名を入れて出て来たもの

New post (Cytotoxic Drug Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| Roche, Eli Lilly, Celgene, Sanofi, eisai, Sumitomo Dainippon Pharma – Apsters News) has been published on FUNDSWIFT – https://t.co/4yzfwj7wW4 pic.twitter.com/fEus7AeoVx

— FundSwift (@fundswift) July 8, 2020

Who would want a simple solution?

"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U

— sandeep chakraborty (@sanchak74) June 12, 2020

Great to see so many pharma companies sharing assets and expertise to support research into COVID-19…Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, J&J, Merck, Novartis, Pfizer, and Sanofi. https://t.co/wtWagRqEV5 pic.twitter.com/6pq6mPl4Cm

— Jennifer Harris (@jnharris1189) March 26, 2020

Sanofi and Eisai Pharma are joining Eli Lilly in a lawsuit to overturn a ruling to end the patent protection of Cialis. Read more to find out the implications for patent claims for other pharmaceutical companies: https://t.co/kojTpbi2cl

— INCUBATE (@incub8coalition) July 17, 2019

Breast Cancer Therapeutics Market Factors That Can Have A Sizable Impact On Industry Growth With Players Like AstraZeneca plc, Eli Lilly and Company, Eisai, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Pfizer https://t.co/fizvl2Uiuq via @openPR

— Dr. Maddys (@Maddys53920205) April 18, 2019

Rectal Cancer – Pipeline Review, H2 2018 Featuring AbbVie, Amgen, Eisai, Eli Lilly, Merck, and more – ResearchAn.. https://t.co/7K2X5TDpLA

— Financial Buzz (@financialbuzz) October 19, 2018

The key industrial players in the anti-migraine drugs sales market include Abbott Laboratories, Inc., Eisai Inc., Eli lilly and Company, Pfizer Inc., Astra Zeneca plc. and Glaxo SmithKline Plc. https://t.co/POypY1bebe

— Amit Rade (@Market_Updates_) February 22, 2018

Other companies in the life sciences #COVID19 consortium are @BDandCo, @Boehringer, @biomerieux, Eisai, @LillyPad, @GileadSciences, @GSK, J&J, @Merck, @merckgroup @Pfizer and @sanofi

— Jim Sheldrake (@jimsheldrake) March 26, 2020

It was great to start day two at Biopharma mission presenting #Stemnovate to leadership in India @AstraZeneca, @GSK, @Sanofi, @Abbott, @Amgen, @NestleSkin, @LillyPad , @Serdiapharma, @Roche, @Oppilotech , @Eisai……looking forward to the next phase of meetings at Ahmedabad. pic.twitter.com/epxYmUC8uB

— Stemnovate Limited (@StemnovateL) September 25, 2019

Next for our #BIO2015 coverage: @Baxalta @PanCAN @BioCentury & ECL Eisai Co on the 5 P's of Successful Stakeholder Engagement.

— Eli Lilly and Company (@LillyPad) June 16, 2015

Latest Research Report on Bipolar Depression Treatment Market| GSK, Pfizer, Janssen Inc., Eli Lilly and Company, Allergan, Novartis, AbbVie, AstraZeneca, Otsuka Pharmaceutical Companies – Dagoretti News – Dagoretti News https://t.co/ohlTIlHYDa

— BipolarDays.com (@BipolarDaysNews) January 20, 2020

#SmallMoleculeCancerDrugs Market Rapid Growth And Development In Pharma & Biotech Industries 2018-2026 By Key Players Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development, Novartis AG, Pfizer, SANOFI AVENTIS US https://t.co/iuaAxGjYQC

— Michael Jaikishan (@Michaeljaikish1) July 5, 2019

"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK

— James Richardson, MD, MPH (@DocRock54) March 10, 2018

.@TheDDFund $350M raise included $60M from @AARP as part of its #DisruptDementia initiative; fund spearheaded by #biopharma group that included @biogen @LillyPad @GSK @JNJNews Otsuka @pfizer @TakedaPharma

— BioWorld (@BioWorld) June 25, 2018

Otsuka inks deal for rights to migraine drug candidate fremanezumab https://t.co/AcRfmaGiro #biotech @LillyPad

— The Pharma Letter (@ThePharmaLetter) May 17, 2017

Interesting, head of #BorisJohnson's #COVID19 '#Vaccine Task Force', Kate Bingham, on board of DDF Investment Committee – created by 6 leading Pharma giants #GSK, Biogen, Johnson & Johnson, Eli Lilly, Pfizer, Takeda. https://t.co/ZOZ6Re3rxK

— Patrick Henningsen (@21WIRE) September 24, 2020

Biogen, Eli Lilly, Takeda ask staff to work from home to limit coronavirus spread https://t.co/IylUkp7Qse $BIIB $LLY

— FirstWord Pharma (@fwpharma) March 9, 2020

As Biogen grapples with coronavirus crisis, Big Pharmas like Eli Lilly, Takeda hunker down, tell staffers to work from home https://t.co/imJyrr1EQ3

— Endpoints News (@endpts) March 9, 2020

this is new
As Biogen grapples with coronavirus crisis, Big Pharmas like Eli Lilly, Takeda hunker down, tell staffers to work from homehttps://t.co/t6nrWWkjEJ

— John Carroll (@JohnCendpts) March 9, 2020

Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan | @WHO @FujifilmUS @drreddys @ResponseAid @GileadScience @Lillypad @Roche #Covid19 #pneumonia #Biotech #Valhalla #NewYork #Indianapolis #FosterCity #California #Biotech https://t.co/XfSqvA4Xp2

— Aspen Biosciences (@aspenbio) September 24, 2020

The key players in Non-Small Cell Lung Cancer #market include @Novartis, @Merck, @LillyPad, Hoffmann-La-@Roche, @Xcovery, @beyondspring26, @OSEIMMUNO, @sanofi, @Takeda, @abbvie and others.

For more detailed information visit: https://t.co/RWk90xqKhl #LungCancer #Cancer

— DelveInsight (@delve_insight) May 12, 2020

Congratulations again to all finalists in the 2019 @PharmaAwardsIRL and well done to all those in our sponsored category Astellas @bmsnews @LillyPad and @MSDInvents. Looking forward to October 24th.@IrishTimes https://t.co/ijZAo6krPM

— BioPharma Engineering (@BioPharmaE) September 16, 2019

#DRG epidemiology report estimates over 1.5 million people living with #ankylosingspondylitis across the United States, Western Europe and Japan. Check out our detailed global reports for more updates @DRGinsights #spondylitis #FDAapproval @US_FDA @LillyPad https://t.co/0CjXXNZN4T

— DRG Epidemiology (@DRG_Epi) August 27, 2019

#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC

Read: https://t.co/Ra1FDwHAXE @Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr

— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019

Eli Lilly (@LillyPad) has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety concerns over a new breast cancer drug in Japan https://t.co/FEpzrbD2aM

— pharmaphorum (@pharmaphorum) May 22, 2019

#DiabetesCellTherapy
Scientists from US and Japan have devised a #newTissueEngineering method to tackle #vascularity problem of transplanted cells
Companies like @LillyPad @Sigilon_Inc are involved in Diabetes cell therapy development
For details click https://t.co/oJMBgdLQ2l

— Roots Analysis (@RootsAnalysis) May 9, 2018

@LillyPad keeps #Alimta patent in Japan for now, new challenges on the way$LLY https://t.co/bplSR75D4o

— Pharmacutical Daily (@PharmacDaily) February 2, 2017

The #ChicagoOsaka Women’s Leadership Forum featured our CEO Andy Zopp, @1871Chicago CEO @BetsyZEO, Mie Kitano of @LillyPad Japan, President Sachiko Morita of Terrace, and @UnivKansai faculty Masumi Shiraish to discuss global gender equality and #womenleaders in business. pic.twitter.com/tbYDfed5MT

— WorldBusinessChicago (@WorldBizChicago) October 24, 2018

Last week, we helped commemorate @LillyPad’s new office in Kobe, Japan. The company has been headquartered in Indianapolis for more than 140 years. #INJapan pic.twitter.com/Ik6MeY96az

— Indiana in Japan (@InvestIN_Japan) July 17, 2018

Indiana is home to 280+ Japanese businesses & Hoosier firms like @LillyPad, @Cummins, @CookMedical, @zimmerbiomet have facilities in Japan. pic.twitter.com/5RkAw6fv24

— Indiana Economic Development Corp. (@Indiana_EDC) September 12, 2017

#EDGEX2018 Speaker Fun Fact: Newt Crenshaw served as the president of @LillyPad in Japan, where he and his wife also helped establish a new @YoungLife ministry. Join us on October 5 as Newt shares his #leadership journey with us! https://t.co/nSglOE045U pic.twitter.com/r8EBLtRKv4

— EDGE Mentoring (@EDGEMentoring) June 13, 2018

@LillyPad #Drug Receives #Approval in #Japan https://t.co/X7VKcQ3DEi pic.twitter.com/w4Mgo6jIKK

— IMA (@IMA1901) July 7, 2017

#TPP "Allied for Innovation" Experts discuss US/Japan common #IP values @globalIPcenter @ITIFdc @USCC_Asia @LillyPad pic.twitter.com/V0yb52OMcW

— Patrick Kilbride (@pjkilbride) April 24, 2015

The U.S., Japan and China were standout markets in Q2 2016. Find out more: https://t.co/4KIV3ZB3nm $LLY pic.twitter.com/d1GMjXxAcQ

— Eli Lilly and Company (@LillyPad) July 27, 2016

Drivers of our Q1 #earnings results include the United States and Japan. Learn more: https://t.co/N0eQxNMDXJ $LLY pic.twitter.com/MRA9JrIGtV

— Eli Lilly and Company (@LillyPad) April 27, 2016

We celebrated Lilly #Japan Day by getting down to the art of the matter. https://t.co/oZFXQWVgrg pic.twitter.com/A54opqm4qq

— Eli Lilly and Company (@LillyPad) December 1, 2015

Speakers shared Lilly #Japan's importance on our 2nd-largest affiliate's 40th anniversary. https://t.co/Ix2v1clkrP pic.twitter.com/23lN8dkp3H

— Eli Lilly and Company (@LillyPad) November 29, 2015

Our #Japan affiliate just marked its 40th anniversary. We held Lilly Japan Day in its honor! https://t.co/Ix2v1clkrP pic.twitter.com/l1SMDRnvWI

— Eli Lilly and Company (@LillyPad) November 25, 2015

Performers took center stage as we celebrated our #Japan affiliate's 40th anniversary! https://t.co/Ix2v1clkrP pic.twitter.com/M61jKy49jf

— Eli Lilly and Company (@LillyPad) November 27, 2015

We're glad to share growth in the U.S. and Japan in Q3. https://t.co/aAFVq1fpjY #earnings $LLY pic.twitter.com/HqKjUjRSdQ

— Eli Lilly and Company (@LillyPad) October 22, 2015

　https://twitter.com/LillyPad/status/459766514456215552
　https://twitter.com/LillyPad/status/458323201479946240

https://twitter.com/Roxann_Minerals/status/975914779859701762

$LLY Here are the Accord Healthcare/Daiichi Sankyo/Eli Lilly IPR final determination docs. https://t.co/bckhh1Qaw8 https://t.co/iCIt9roKAz

— TradeHawk (@TradeHawk) September 12, 2016

Global Cardiovascular Therapeutics Market 2020-2024 | Evolving Opportunities with Astellas Pharma, Inc. and Eli Lilly and Co. | Technavio https://t.co/w46yHRXwvw pic.twitter.com/z9bYWSGkzP

— Latest News from Business Wire (@NewsFromBW) April 10, 2020

Ependymoma Market Future Innovation Strategies by 2029 | Eli Lilly, Astellas and DNAtrixhttps://t.co/kXAemzI6Mt #news #pharma #pharmiweb

— Pharma News (@pharminews) March 30, 2020

Cancer Treatment Drugs Market Size, Growth, Share and Top Players to 2026: Amgen, Roche, Novartis, Johnson & Johnson, Pfizer, Eli Lilly, Astellas https://t.co/9tASuYljgR pic.twitter.com/CxDF4MHAOF

— PressRelease.cc (@PressRelease_cc) October 1, 2019

Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates https://t.co/VPhVGWIRf9 @nateraymond ($) pic.twitter.com/1HovatBRq7

— Reuters Legal (@ReutersLegal) April 5, 2019

Antibiotics Market Future Outlook to 2025 – GSK, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Astellas Pharma, Pfizer, Janssen Inc. and Abbott https://t.co/gErVJuGW0d via @openPR

— Mohammed Alsogaih (@MAlsogaih) September 1, 2018

Eli Lilly, Astellas, China’s ShangPharma and Simcere helped raise $171M for Partners HealthCare System's life science fund. https://t.co/5wJ6YPKUJj

— FierceBiotech (@FierceBiotech) November 9, 2017

Great news! Sekisui has been named in the 2018 Global 100 World’s Most Sustainable Corporations: https://t.co/IQZWtjm4cy Congratulations to UCB, Merck, Allergan, Sanofi, AstraZeneca, Eli Lilly, Takeda, GSK, Novartis, J&J and others who also placed! pic.twitter.com/y6cmX0BRiX

— Sekisui XenoTech (@XenoTechllc) January 26, 2018

Breaking: Jury hits Eli Lilly, Takeda with $9 billion penalty. http://t.co/EIqfJ7JDRl

— IndyStar (@indystar) April 8, 2014

U.S.A. アメリカ Vol.113（Massachusetts マサチューセッツ州 Vol.2: pharmaceutical corporations 製薬会社）

All the below links and tweets are in English.

取り急ぎ以下貼っておきます。

Massachusetts Vol.19 (corporations: Moderna)
Massachusetts Vol.20 (corporations: Biogen)

ツイッター検索で上記2製薬会社各社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273): https://t.co/jpsGTOv9BQ pic.twitter.com/fo0XC7pCXo

— Moderna (@moderna_tx) August 28, 2020

.@TakedaPharma sets up deal to distribute @moderna_tx’s #COVID19 #vaccine in Japan: https://t.co/h7QCDUi89A

—#biomanufacturing #bio #biopharma #pharmaceutical #pharma #healthcare #manufacturing #coronavirus #pandemic pic.twitter.com/sTJPWEkjXv

— American Biomanufacturing (@BioMfg) September 2, 2020

Moderna to potentially supply Japan with 40M doses of COVID-19 vaccine @moderna_tx https://t.co/pRlHBWh3uk

— The Science Advisory Board (@ScienceBoard) August 28, 2020

American biotech company @moderna_tx has confirmed it is in discussions with #Japan's government over the potential purchase of 40 million or more doses of COVID-19 #vaccine.https://t.co/XKNJ7uC317

— The Jerusalem Post (@Jerusalem_Post) August 28, 2020

The #US-based biotech company #Moderna (@moderna_tx) has confirmed talks to supply 40 million doses of its potential #COVID19vaccine to #Japan. pic.twitter.com/qYDWaNTdQm

— IANS Tweets (@ians_india) August 30, 2020

“The [@moderna_tx] #vaccine candidate… would be distributed in Japan by @TakedaPharma, beginning in the first half of 2021… #Japan has already signed agreements with other drugmakers such as @Pfizer & @AstraZeneca, as well as local ones like #Shionogi & Co…” #COVID19 https://t.co/awQJyQhnpN

— Mark Warner (@MAAWLAW) August 28, 2020

COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"

— ClinicalBid (@ClinicalBid) June 30, 2020

We are proud to announce that we are working with @biogen Japan LTD. to create a system to respond faster and more accurately to questions from patients, the media, physicians & other constituents at its Medical Information Department (MID).

Read more: https://t.co/7R11MuIgCa

— Lexalytics (@Lexalytics) September 18, 2019

Program two "Gene Lab" @miraikan in Japan- Students worked on experiments w/electrophoresis and recombining DNA! #STEM #HandsOnScience pic.twitter.com/9AZ3JUGqgg

— Biogen (@biogen) March 21, 2017

Our Rare Disease treatment is now approved across the globe in Australia, Brazil, Canada, EU, Japan, Switzerland and the US #ProudMoments2017 pic.twitter.com/5lyBePTfYs

— Biogen (@biogen) December 22, 2017

Heading to Japan to be part of #WCN17 focused on the future of #neurology. Follow @Biogen for the latest! pic.twitter.com/A4yU2kFTci

— Biogen MS (@biogenms) September 15, 2017

Exciting moments w/ students @miraikan in Japan during "Gene Lab" hands-on experiment events – “E-coli glowing in the dark”! #STEM #Science pic.twitter.com/ak7wee6o7L

— Biogen (@biogen) March 13, 2017

Great to have @BiotechTour ambassadors & @miraikan representatives at our Japan office @sciencecenters #WBT2015 #STEM pic.twitter.com/MwPNSmJ9TH

— Biogen (@biogen) August 3, 2015

.@BiotechTour 2015 continues with it's next stop in Tokyo, Japan @miraikan (August 8 ceremony) http://t.co/12YAJjg4zn #WBT2015 #STEM

— Biogen (@biogen) July 28, 2015

An amazing day at @miraikan WBT festival! Thank you @biogen and @ScienceCenters for your support in Japan #WBT2015 pic.twitter.com/mqNeOMi9nU

— WorldBiotechTour (@BiotechTour) August 8, 2015

This year we celebrated our 40th anniversary with events in the U.S., Japan and Switzerland. Almost 2K employees, experts, physicians, patients and reporters were able to join us to reflect on the important moments that shaped our past, and our bright future. #ProudMoments2018 pic.twitter.com/iTnlHrhFZz

— Biogen (@biogen) December 11, 2018

#DRG epidemiology report estimates more than 15,000 people diagnosed with #SMA across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #spinalmuscularatrophy #RareDiseaseDay @biogen https://t.co/PguIonrUSW

— DRG Epidemiology (@DRG_Epi) March 5, 2020

#DRG epidemiology report estimates more than 15,000 people diagnosed with #SMA across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #spinalmuscularatrophy #EAN2019 @biogen https://t.co/vNfzsxdEAd

— DRG Epidemiology (@DRG_Epi) July 3, 2019

#DRG epidemiology report estimates more than 35,000 diagnosed prevalent cases of #amyotrophiclateralsclerosis across the United States, Western Europe and Japan. Detailed report available now @DRGinsignts #ALS #WorldALSDay @biogen https://t.co/pE5tSpaPpw

— DRG Epidemiology (@DRG_Epi) June 24, 2019

More than 10 million people are living with #Alzheimersdisease across the United States, Western Europe and Japan. Stay tuned for more updates on #DRG global epidemiology data @DRGinsights @biogen #AlzheimersAwarenessMonth https://t.co/MmNdFkPrzQ

— DRG Epidemiology (@DRG_Epi) November 6, 2018

How about a deal with @SangamoTx to better exploit protein homeostasis? Hematology is unpartnered @ScienceAtBMS @bmsnews @JoeSzustakowski.
Partners include @sanofi @NovartisScience @pfizer #takeda @GileadSciences @KitePharma @biogen $SGMO $BMY $PFE $NVS $SNY $GILD $BIIB https://t.co/tJzQPwFTgB

— biotech 2050 (@Biotech2050) July 30, 2020

Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx

— Open Targets (@targetvalidate) June 21, 2019

Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW

— Sanger Institute (@sangerinstitute) December 5, 2017

The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovuk https://t.co/tdtENajGGx

— The Dementia Discovery Fund (@TheDDFund) August 9, 2018

.@TheDDFund $350M raise included $60M from @AARP as part of its #DisruptDementia initiative; fund spearheaded by #biopharma group that included @biogen @LillyPad @GSK @JNJNews Otsuka @pfizer @TakedaPharma

— BioWorld (@BioWorld) June 25, 2018

Former @biogen R&D guy @michael_gilman has a new biotech today, Obsidian, founded in 2015 by Atlas. A $50M Series A round was led by GV, the venture arm of Alphabet, & includes Atlas and the venture arms of Takeda and Amgen. by @BosBizMax https://t.co/HPYNg8DZaA

— Don Seiffert (@BosBizDon) December 6, 2017

#Biotech Industry in #Boston Reacts to #Coronavirus, Implements Containment Measures | @Biogen execs instructed to quarantine and isolate themselves from loved ones, and @Takeda implementing work-from-home for workforce | #COVID19 #SARSCoV2 #2019nCoV https://t.co/80oCHVVDbN

— Patrick Henry Warren (@phwarren360) March 9, 2020

https://twitter.com/bmd_congress/status/1165337983094067201

Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2

— Sanger Institute (@sangerinstitute) December 5, 2017

ADI would like to thank our supporters whose generosity enabled us to run yet another successful #WorldAlzMonth campaign; in particular, Acadia Pharmaceuticals, @biogen, @JanssenUK, @Lundbeck, Otsuka & @Roche. Thank you! pic.twitter.com/Pej52CpUhz

— ADI (@AlzDisInt) October 2, 2020

Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus | @Roche @Eisaius @Biogen @Quest @HMHNewJersey @hallnursing #Nutley #NewJersey #Cambridge #Massachusetts #Biotech #neurodegenerative #diabetes #cancer #alzheimer #parkinson https://t.co/ce0EkdSrJF

— Aspen Biosciences (@aspenbio) August 12, 2020

Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus | @Roche @Eisaius @Biogen @Quest @HMHNewJersey @hallnursing #Nutley #NewJersey #Cambridge #Massachusetts #Biotech #neurodegenerative #diabetes #cancer #alzheimer #parkinson https://t.co/IkXPDuB59M

— Pharm2Market (@pharm2market) August 12, 2020

Biogen and Eisai Complete the Submission of BLA to the US FDA for Aducanumab to Treat Alzheimer’s Disease @biogen @EisaiUS https://t.co/A9YmZfSPUW pic.twitter.com/rGx3wODNiz

— PharmaShots – Incisive news in 3 shots (@Pharmashot) July 9, 2020

Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer’s Disease @biogen https://t.co/nSOsjsoRZo pic.twitter.com/WrFji1EsGZ

— PharmaShots – Incisive news in 3 shots (@Pharmashot) March 22, 2019

Biogen, Eisai seek priority US #FDA review of #Alzheimer's drug @biogen https://t.co/1w1SRBawS1 pic.twitter.com/1rd7XK4AdE

— Market Intelligence: Healthcare (@SPGMIHealthcare) July 9, 2020

Global #Alzheimers #Drugs Market 2019 — Eisai Pharmaceuticals, @Allergan, Amgen, @Biogen https://t.co/g6tC6YC5KB

— Marketstudy (@Marketstudy1) October 25, 2019

Biogen, Eisai revive plans for Alzheimer’s drug #Alzheimers @biogen https://t.co/0ChzgxABqB

— Pharmacy Business (@PharmacyBiz) October 24, 2019

This is incredibly disappointing news, but just another reason we have to keep up the fight. Alzheimer's is relentless, so are we. #endalz @biogen @eisai

Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment https://t.co/skleIwPUcw

— Carey Ann Comeau (@careyanncomeau) September 17, 2019

Due to unfavorable risk-benefit, @Eisai_SDGs & @biogen discontinue Ph3 #clinicaltrials of #elenbecestat vs early #Alzheimers #BACE inhibitor was studied in patients w/ mild #cognitive impairment or mild AD + #amyloid pathologyhttps://t.co/MPKXpGK141 #neuroscience #dementia pic.twitter.com/ik4Dc4JCpH

— DDNews Online (@DDNewsOnline) September 13, 2019

Eisai kickstarting alternate Alzheimers’ drug after failure of Aducanumab: https://t.co/ccyHcYCEKl @FierceBiotech @EisaiUS @Biogen #Alzheimers #mentalhealth #drugdiscovery #medicine

— NCBCenter (@NCBCenter) March 27, 2019

@Eisai_SDGs, @biogen kick-off phase 3 testing early #Alzheimer's disease antibody, amid dropping #aducanunab trial https://t.co/jmNie2FFf8 pic.twitter.com/8PFtoy4mgr

— Pharmacutical Daily (@PharmacDaily) March 22, 2019

https://twitter.com/HeidiCreighton/status/1109772708148113409
https://twitter.com/HeidiCreighton/status/1109064555542523906

Disappointing news, @biogen and Eisai have announced the decision to discontinue the EMERGE and ENGAGE Phase III clinical studies of #aducanumab in #Alzheimer’s diseasehttps://t.co/b0pCqyNZFc pic.twitter.com/uZjfSsaCwL

— Alzheimer Europe (@AlzheimerEurope) March 21, 2019

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease https://t.co/9aYlZeFYCV @biogen @EisaiUS More life science business news at [LSUS] at https://t.co/WILuBJwPqp pic.twitter.com/a4tJEPaJ1m

— [iito] Life Science (@iitoLifeScience) March 21, 2019

“We used to have to squint and look at things to feel like, ‘OK, maybe this could work.’ I think this is really giving us a real feeling that we’re making a lot of progress,” PMC's Dr. David Wolk told @whyy regarding the @biogen/Eisai research results. https://t.co/cKjfs4vtDN

— Penn Memory Center (@Penn_Memory) July 31, 2018

Eisai Co. & @Biogen revealed data showing their experimental drug slows the progression of #Alzheimers, but experts like PMC Co-Director @jasonkarlawish say they would like to see a larger, longer study conducted to further assess risks and benefits. @WSJ https://t.co/L1e06YnWjn

— Penn Memory Center (@Penn_Memory) July 30, 2018

.@biogen and Eisai's #Alzheimers drug demonstrated in a clinical trial that it significantly slowed cognitive decline and more for #pharma #marketers to know. $BIIB $GILD $AMGN #healthcare #HealthInsurance https://t.co/QebzaE0NAb pic.twitter.com/zHPfvrOsBx

— MM+M Magazine (@MMMnews) July 26, 2018

News for #pharma #marketers: Thurs, July 26
– @biogen and Eisai's #Alzheimers drug slows cognitive decline
– @GileadSciences CEO to step down
– @Amgen #migraine treatment faces difficulties with insurers$BIIB $GILD $AMGN #healthcare #HealthInsurance https://t.co/QebzaDJcID pic.twitter.com/p8HskyIm4K

— MM+M Magazine (@MMMnews) July 26, 2018

.@Biogen and Japanese drugmaker Eisai created a surge in hope for an experimental #Alzheimers drug called BAN2401, after the companies announced positive results in a late-stage trial. But did the market overreact to the #data? #pharma #healthcare https://t.co/FlAEq43bX5 pic.twitter.com/KWgtEpyMsO

— MM+M Magazine (@MMMnews) July 14, 2018

Eisai and Biogen's Alzheimer's drug slows progression in Phase 2 trials https://t.co/q34CgTkBpR #AlzheimersDisease #Alzheimers #Phase2 @EisaiUS @biogen

— Pharmafocus (@Pharmafocus) July 26, 2018

Looks like Investors, analysts remain to be convinced over @EisaiUS @Biogen's #BAN2401 in #AlzheimersDisease even after more details of promising Phase II data

Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical https://t.co/YYao6VbYT2

— Ian Haydock (@ScripIanHaydock) July 26, 2018

Results of @Biogen and #Eisai clinical trial show #Alzheimers treatment reduced buildups of amyloid plaque in the brain by 93% and slowed progression of the disease 30-47% https://t.co/NIOMoy3SYG $BIIB pic.twitter.com/fwfkvkWzSM

— Jeff Cotrupe (@jeffcotrupe) July 25, 2018

Clinical trial results are in! Eisai & Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months @biogen https://t.co/kaoS6IQKJR pic.twitter.com/4glbrp4Hc7

— Neural Cell News (@NeuralCell) July 13, 2018

Eisai and @Biogen announce positive phase 2 Alzheimer’s data on BAN2401 anti-amyloid beta protofibril antibody. Patients exhibited slowdown in symptoms and reduced plaque in the brain. https://t.co/19Vp6MgFLI Good news and verification of amyloid beta as a therapeutic target

— Upperton (@UppertonLtd) July 12, 2018

We're closer than ever to treating #Alzheimer's with two drugs from @Biogen and @Eisai that do what #BigPharma hasn't been able to yet. https://t.co/uEccuWjPRX

— Tech2 (@tech2eets) July 10, 2018

@EisaiUS and @biogen Phase 2 trial for BAN2401 in #Alzheimers #patients, GlobalData figures say the global Alzheimer’s market will reach $14.8bn by 2026, so Eisai and Biogen can still expect to achieve significant sales for their product. https://t.co/mNRhbYywLU

— GlobalData Pharma (@Pharma_GD) July 6, 2018

@biogen @EisaiUS news – a win for the #amyloid hypothesis "BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack" via @PharmaScrip #Alzheimers pic.twitter.com/b7Srr8hCf6

— OptimumComms (@OptimumComms) July 6, 2018

https://twitter.com/akalali/status/1015103726577639424

#Eisai – #Biogen to advance #Alzheimers drug, provide fresh hope https://t.co/UHQLpoVTGA #ETHealthworld @ETHealthWorld @biogen #BAN2401 #AlzheimersDisease #pharma

— Plexus Ventures (@PlexusVentures) July 25, 2018

@biogen takes up option to co-develop #Eisai #AD drug https://t.co/mfwmLP2VXu @PharmaTimes #AlzheimersDisease #aducanumab

— Plexus Ventures (@PlexusVentures) October 25, 2017

Eisai sells RTP facility to @Biogen; results in 35 layoffs http://t.co/iqBdzh1Ski pic.twitter.com/m7S3Xolkzy

— Boston Business Journal (@BosBizJournal) July 16, 2015

#Leukemia_Therapeutics_Market: Growing at a CAGR of 6.6% over the forecast period of 2019-2025.
For More Details: https://t.co/jmnagRx2bn @Celgene @Eisai_SDGs @SanofiGenzyme @bmsnews @Novartis_AG @biogen @Roche @GSK @pfizer pic.twitter.com/BtaRV399Eb

— Infinium Global Research (@infiniumglobal1) August 24, 2019

Very interesting consensus white paper from @MichaelJFoxOrg: A proposed roadmap for #Parkinsons proof of concept clinical trials investigating compounds targeting alpha synuclein – @biogen @VAInstitute @Eisai @LumosPharma @JCedarbaum @BrundinPatrik https://t.co/5h4mu4a70F pic.twitter.com/ozaqisV10M

— ScienceofParkinsons (@ScienceofPD) November 8, 2018

Would this treatment resolve these issues from #Inflammation as well?#Dementia @nih_nhlbi @biogen @EisaiUS @eisai @HopkinsMedNews https://t.co/V7k8ZwqTBd pic.twitter.com/79WFvREHz3

— BW (@fxrseen) July 6, 2018

Switzerland スイス Vol.2（pharmaceutical corporations 製薬会社）

All the below links and tweets are in English.

取り急ぎ以下貼っておきます。
Switzerland Vol.5 (pharmaceutical corporations: Novartis)
Switzerland Vol.6 (pharmaceutical corporations: Roche)
Switzerland Vol.7 (pharmaceutical corporations: Lonza, Actelion, Ferring Pharmaceuticals)

ツイッター検索で上記5製薬会社各社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Last, reminding folks that novel pancoronavirus inhibitors are being developed by other big pharmas (Novartis, Takeda, Gilead, etc), who are moving very quickly: https://t.co/dn5JUpLXUy

— Lisa Jarvis (@lisamjarvis) September 17, 2020

Takeda just made a huge investment in cell therapy programs – a new R&D cell therapy manufacturing GMP facility in Boston. To cover 5 collab programs – Yamanaka, Rezvani, Sadelain, Noile-Immune Bio, GammaDelta Tx https://t.co/PNs2SXMubD Reminds me Novartis in the past…

— Alexey Bersenev (@cells_nnm) September 15, 2020

Global Candida Infections Drugs Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Abbott, Pfizer Inc., Novartis AG, Merck & Co., Inc, Sanofi, Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plchttps://t.co/d7povpUALz #new

— Pharma News (@pharminews) September 8, 2020

Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia

— Pearl Freier (@PearlF) September 6, 2020

Fighting stigma — Alzheimer's Disease Consumption Market is Booming Worldwide 2020-2027 | Allergan, Eisai …: Alzheimer's Disease Consumption Market is Booming Worldwide 2020-2027 | Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer. https://t.co/AEaRUSbxKP

— STIGMABASE | EDU (@stigmabase) August 24, 2020

Otsuka beats back Novartis opposition with $15M purchase of smart pill developer Proteus https://t.co/bdi5MasNwb – was this the largest “de-valuation” of a #digitalhealth company ? Anyone have the stats ?

— Eugene Borukhovich (@HealthEugene) August 21, 2020

Discover the latest in the pharmaceutical legal landscape from legal experts who are shaping the landscape. Learn from, and liaise with, the likes of #Astellas Pharma, #AstraZeneca, #GSK, #Merck, #Novartis International AG, #Pfizer, #Teva, and many more! https://t.co/dqYm5O6NtJ pic.twitter.com/DJ93ECtTXO

— Pharma Regs – Informa Connect (@PharmaRegsIC) August 12, 2020

Sugar Coated Tablets Market Overview & Potential Growth Opportunities 2023| Key Players:Pfizer, Novartis, GSK & Eisai : Radiant Insights, Inc. https://t.co/0qhLWEgm0R pic.twitter.com/fAypRRPKo8

— ABNewswire (@ABNewswire) July 31, 2020

Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Novartis announces new drug approved in Japan for patients with a specific mutation in advanced non-small cell lung cancer. #NSCLC #NovartisNews

— Novartis News (@NovartisNews) June 29, 2020

Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal https://t.co/XfZZGdOed5 pic.twitter.com/lH20KeVBns

— Reuters (@Reuters) June 29, 2020

Royalty Pharma's portfolio..AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta-all pay royalties to this company https://t.co/Y3l3KZvq1c

— MedicalQuack (@MedicalQuack) June 20, 2020

Guess who are stakeholders of the NICE guidelines for psychosis?

Astrazeneca UK Ltd, Pfizer, Sanofi, Roche, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly, Janssen, Lundbeck, Novartis, Otsuka Pharmaceuticals etc.https://t.co/FQhUw8RHBz

— Nick (@NickWebb30) March 31, 2020

Well done BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck (known as MSD outside the U.S. and Canada), Merck KGaA, Novartis, Pfizer, and Sanofi. https://t.co/f4ATL9azds

— Adam P Roberts (@GCAGATGCAATG) March 26, 2020

Japan approves Novartis' Zolgensma for spinal muscular atrophy in patients under two years old https://t.co/75M3RoPaHb #pharma pic.twitter.com/fBHwt0wNMU

— Pharmafocus (@Pharmafocus) March 19, 2020

https://twitter.com/Kamacintosh/status/1232044166886105089
https://twitter.com/RebeccaDRobbins/status/1222956083301322752

#Trending: Astellas Venture Management, Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B – Business Wire#entrepreneur #venturecapital #vc #startups

Read More Here:https://t.co/OJ7yGj7EpW

— Chuck Russell (@iamChuckRussell) January 14, 2020

Astellas Venture Management Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B: Total Series B Raise of $35 million TScan Therapeutics today announced the completion of its Series B raise with the inclusion of… https://t.co/ovyn92roLF

— Renal Cell Carcinoma (@Renal_Bio) January 9, 2020

Otsuka/Proteus, Novartis/Pear, Sanofi/Verily — pharmas & DtX partners are splitting up left and right. Should startups and investors be worried? @dave_muoio
digs in. https://t.co/vEUJmh5hrE via @MobiHealthNews

— Jonah Comstock (@JonahComstock) December 16, 2019

There are examples of some big Pharma tech partnerships failing Novartis-Proteus. Otsuka-Proteus. Novartis-Pear. Sanofi now exits. But -while these experiments may not have paid off—there still seems to be appetite for innovation and AI. https://t.co/wBH4kvdTix

— Vasudev Bailey, PhD (@vasudevbailey) December 11, 2019

Biotech’s second year of red-hot takeovers is set for a strong finish with Astellas Pharma’s $3 billion buy and Novartis’s $6.8 billion deal for Medicines Co. https://t.co/H1o1vhp3vQ pic.twitter.com/TesYaDcEtn

— Bloomberg (@business) December 4, 2019

As mentioned earlier, Verily, Google's health care division, is also collaborating with Sanofi, Novartis, Otsuka and Pfizer to help them identify suitable patients for clinical drug trials. #digitalmarketing #optimization #growthhacking https://t.co/X1jXvUzYZu

— MRVSKY (@mrvskypro) December 1, 2019

Pharmaceutical Technology – #October’s top #news #stories https://t.co/xHDYOFwX6W #UCB #RA | #Novartis #Microsoft | #Sobi #Dova | #Sanofi US #manufacturing | #Alexion #Achillion | #Bavarian Nordic #GSK | #Daiichi #Astellas | #Ipsen #Blueprint | …

— GESDAT GmbH (@GESDAT) November 5, 2019

Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7

— ABNewswire (@ABNewswire) September 13, 2019

Anokion helped launch the Cambridge-based start-up it acquired today, Kanyos, back in 2015. Kanyos' early backers also included Versant Ventures, Astellas, and the venture arms of Novartis and Novo Nordisk. https://t.co/R6CzYpsmWn

— Kate Sheridan (@sheridan_kate) September 11, 2019

Google sister-company Verily is teaming with big #pharma companies such as Novartis, Sanofi, Otsuka and Pfizer on clinical trials with the goal to aggregate data across a variety of sources. Read more: https://t.co/nsC84fgcWY

— BrackenData (@BrackenData) July 13, 2019

Verily has formed alliances with Novartis, Sanofi, Otsuka, and Pfizer to work on clinical trials. So, what do they get out of the deal? https://t.co/QmgSYRsMhN

— STAT (@statnews) May 26, 2019

Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems. https://t.co/HiKfv83vzM

— BioSpace (@biospace) May 21, 2019

The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf

— FierceBiotech (@FierceBiotech) May 21, 2019

Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq #R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth

— Vitaly Health (@HealthVitaly) May 19, 2019

Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800 https://t.co/dSZ1bpaPtM pic.twitter.com/pzy74432N2

— Reuters (@Reuters) May 15, 2019

Takeda selling Xiidra to Novartis: Takeda Pharmaceutical has entered into an agreement to sell Xiidra to Novartis for up to $5.3 billion. The sale will enable Takeda to focus on its key business areas of gastroenterology, rare diseases, plasma-derived… https://t.co/HnTfEdUjyK

— Keratomania | Keratoconus Advocacy Network (@Keratomania) May 9, 2019

Somewhere out there, Flemming Onskov is chuckling tonight —
Novartis buys Takeda’s new dry eye drug in $5.3B deal, hiring on 400 staffers in a blockbuster push on ophthalmology$NVS https://t.co/Y9bP1tmV87

— John Carroll (@JohnCendpts) May 8, 2019

$NVS $TAK – Novartis eyeing Takeda eye disease unit – Bloomberg https://t.co/E7Ko5Rzkxc

— Breaking News (@MarketCurrents) May 8, 2019

And another lobbyist fan of Buttieg, John Michael Gonzalez, is a DCCC bundler who reps PhRMA, Amgen, Astellas Pharma U.S., AstraZeneca, Celgene, Merck, and Novartis as well as Cigna, America’s Physician Groups and InnovaCare. https://t.co/UAnYI3VRyi https://t.co/7wAWNG5RpB

— Alex Kotch (@alexkotch) April 24, 2019

8 New drug structures revealed at #ACSOrlando….see them here !
Companies include: Amgen, Abbvie, Novartis, Takeda, Pfizerhttps://t.co/ZE68xbb5r7 pic.twitter.com/tYbPMJ45Gj

— Organic Process Research & Development (@OPRD_ACS) April 5, 2019

We're excited to share that we have raised $31M from Novartis, Ping An Group, Chiesi Group, GuideWell and Otsuka to invest in Health Transformers #DigitalHealth #StartUpHealth #Moonshots https://t.co/ooWXzwiUrl

— StartUp Health (@startuphealth) September 25, 2018

Sun Pharma buys 14 drug brands from Novartis in Japan https://t.co/r8KEuqrOVT pic.twitter.com/l9MqFv1bwC

— Business Today (@BT_India) March 30, 2016

Sun Pharma agrees to buy 14 drug brands from Novartis in Japan https://t.co/hd6hsmpSKS pic.twitter.com/nq2uII5WfZ

— Hindustan Times (@htTweets) March 30, 2016

Novartis psoriasis drug approved in Japan http://t.co/THMqWEqEC3

— MarketWatch (@MarketWatch) December 26, 2014

　https://twitter.com/pharmalot/status/562637508815900674
　https://twitter.com/STForeignDesk/status/506366489046159360
　https://twitter.com/DunyaNews/status/484281346127175680

Roche to look for approval of COVID-19, influenza test in Japan#roche #test #japan https://t.co/6xcMG2LcBO

— Breaking the News 24/7 (@Breaking24Seven) September 11, 2020

Roche Seeks Approval For Covid, Flu Combo Test In Japan – Nikkei https://t.co/2M41ejQXoG

— LiveSquawk (@LiveSquawk) September 11, 2020

The story behind the vitamin cartel of the 1990s, one of the most harmful and far-reaching cartels ever, provides a graphic example of the unscrupulous business ethics of the pharmaceutical industry.#vitamincartel #Roche #BASF #Takeda https://t.co/qFRSiK0LYF

— Dr. Rath Foundation (@Dr_Rath_News) August 15, 2020

Chances of @Roche’s etrolizumab challenging @Takeda’s fast-growing Entyvio in the #ulcerativecolitis market look much diminished after top-line phase 3 results are revealed https://t.co/dNPqUYawVs

— pharmaphorum (@pharmaphorum) August 10, 2020

The Latest Info On Pharmaceutical Treatments And #Vaccines•#GileadSciences•#AbbVie•#Moderna•Johnson&Johnson•#EliLilly•#Pfizer•#GlaxoSmithKline•#VirBiotechnology•#Sanofi•Apeiron Biologics•#CureVac•#Dyadic•#Mesoblast•#Novavax•#Roche•#Takeda https://t.co/De0VjosMjf

— LebensKünstler (@GmmLhDBsc2heyst) March 20, 2020

https://twitter.com/IFPMA/status/1240674566214737920

The Daily Biotech Pulse: European Nod For Roche, Takeda … #biotech #bhivechat #bhivenectar #bhive https://t.co/W0wFVVxzqh

— BHIVE BioTech (@BHIVE_BioTek) September 7, 2019

Takeda v Roche: "Is it plausible? Is it true?" https://t.co/r69KeiEU09 via The IPkat pic.twitter.com/Dh88ug4qPT

— Zivko Mijatovic & Partners (@ZivkoMijatovicP) August 1, 2019

Xconomy – #Bio #Roundup: #Alzheimer’s Fail, #Drug #Price #Plan, #Gene #Therapies & #DRUG #DEVELOPMENTS https://t.co/QWpLu146cB #JnJ #Roche #Sunovion #Alexion #Takeda #Pfizer #Lilly …

— GESDAT GmbH (@GESDAT) February 1, 2019

At $74B, $BMS's $CELG deal is the largest ever outlay for a biotech takeout, topping Takeda-Shire. In terms of valuation, the deal is second only to Genentech’s '09 acquisition by Roche. Read more on today's pre #JPM2019 mega-deal in @BioCentury Extra: https://t.co/nC6wKWZxUW pic.twitter.com/EULYhKBfic

— BioCentury (@BioCentury) January 3, 2019

Japan approves Roche's entrectinib in tissue-agnostic indication, Daiichi's AML therapy quizartinib, Alnylam's Onpattro and Alexion's Ultomiris $ROG $ALNY $ALXN https://t.co/TON7QXZX5d

— BioCentury (@BioCentury) June 18, 2019

BioCentury's Sept. 12 clinical roundup includes Celgene plans for regulatory submission in AML on Phase III meet; plus clinical updates from Roche, Tocagen, Adverum, Daiichi Sankyo and more $ROG $TOCA $ADVM $APPL https://t.co/MEXuxEYsAm

— BioCentury (@BioCentury) September 13, 2019

BioCentury's March 26 product development roundup includes approval of Pear's digital therapeutic for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax $JAZZ https://t.co/W7EATOXux0

— BioCentury (@BioCentury) March 27, 2020

https://twitter.com/RebeccaDRobbins/status/1222956083301322752

Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql

— Science Examiner (@ScienceExaminer) October 7, 2019

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug https://t.co/bISxvzKf94 pic.twitter.com/BYUzQaMd4B

— Reuters Business (@ReutersBiz) March 29, 2019

AstraZeneca Plc will pay up to $6.9 billion (5.2 billion pounds) to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

"AstraZeneca pays up to… https://t.co/4TTdJW5BNp

— kristoferkawas (@kristoferkawas) March 29, 2019

Interested in #immunotherapy & #immunohistochemistry?

Check out DDNews’ e-news w/ stories from MorphoSys, Roche, Daiichi Sankyo & UCSD

PLUS resources from sponsor Cell Signaling Technologyhttps://t.co/ueiomZAZMq #immunooncology #diagnostics #antibodies #CellTherapy #microRNA pic.twitter.com/IwTXzDT7s3

— DDNews Online (@DDNewsOnline) February 15, 2019

UK biotech Celleron Therapeutics has bought a licence to develop, manufacture and market emactuzumab, an unwanted drug from Roche’s pipeline that could be used in a rare tendon sheath cancer already targeted by Daiichi Sankyo https://t.co/Olet72u08f

— pharmaphorum (@pharmaphorum) August 12, 2020

Lung Cancer Therapeutics Market Research, Recent Trends and Growth Forecast 2027 | #Roche, #Eli Lilly and company, #Pfizer, #Agennix AG and #Snaofi-Aventis, #Daiichi Sankyo, #AstraZeneca, #GlaxoSmithKline https://t.co/kQhkhOLn48

— A2ZMarketResearch (@A2ZResearch) July 31, 2020

Major Players in the #Musculoskeletal #Disorders #Drugs #Market are F. Hoffmann-La Roche Ltd; GlaxosmithKline Plc; Pfizer Inc; Abbott Laboratories Inc; Daiichi Sankyo Company

Read More @ https://t.co/zAg48gjJ1d #marketresearch #research #TBRC pic.twitter.com/CgSHsx04l1

— Sreeramakrishna TBRC (@sreeramtbrc) June 5, 2020

ASCO: In stomach cancer, AstraZeneca and Daiichi's Enhertu goes where Roche's Kadcyla couldn't https://t.co/QH4teeefRW

— EIPG (@EIPGeu) May 30, 2020

https://twitter.com/HAccordingly/status/1221321860236955649

Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campushttps://t.co/OcqukRYGP5

— John Carroll (@JohnCendpts) August 11, 2020

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc

— FiercePharma (@FiercePharma) July 8, 2020

https://twitter.com/ResearchNews_24/status/1154008113730576384

Lonza Reaches Milestone with Takeda – https://t.co/uYf0bWpOmB pic.twitter.com/oqJ37NniGt

— GMPnews.Net (@GMPnewsNet) January 14, 2019

Lonza, Takeda reach regulatory milestone in oncology tie-up https://t.co/chKQ0JKFRx

— Cleanroom Supplies (@Cleanroomsupply) January 18, 2019

https://twitter.com/JanssenAP/status/1177073498864279552

Sphingosine 1-Phosphate Receptor 1 Market to See Major Growth by 2025 | Actelion, Arena Pharmaceuticals, Astellas Pharma,… https://t.co/JV6hlVG9tZ >>> https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #CI pic.twitter.com/odm4opMknO

— Dr Timos Papagatsias (@_timos_) February 19, 2019

Global Prostate Cancer Therapeutics Market 2026 – Sanofi, Takeda, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Ipsenhttps://t.co/MqR8Y7rxmL #news #pharma #pharmiweb

— Pharma News (@pharminews) June 23, 2020

Global Prostate Cancer Therapeutics Market In-Depth Research on industry & Emerging Growth Factors || Major Players are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Pfizer Inchttps://t.co/fFjHRbxhKX #new

— Pharma News (@pharminews) March 23, 2020

Increase in research & development in oncology therapeutic area is Driving The Global Prostate Cancer Therapeutics Market with Higher CAGR | Major Players are Tolmar INC, Ferring Pharmaceuticals, Takeda pharmaceutical co. Ltd., Teva Pharmaceutical… https://t.co/fSa9mrn6wy pic.twitter.com/asxRZ4JUMe

— Oncology Board (@mb_Oncology) September 21, 2019

Recent articles about Japan 日本関連英文記事 Vol.3

All the below tweets are in English.

Japan’s new prime minister, Yoshihide Suga, picked a status quo cabinet, suggesting he was rewarding the party factions behind his unexpected rise. But the number of women in the cabinet will also decline.https://t.co/R564uIvJjy

— The New York Times (@nytimes) September 17, 2020

The Japanese government has accused Greg Kelly of helping his former boss at Nissan, Carlos Ghosn, hide tens of millions of dollars of pay from regulators.

But when Kelly appeared in court on the opening day of his trial, he faced charges alone. https://t.co/fJm9qEEaae

— The New York Times (@nytimes) September 15, 2020

Since early July, Japan has allowed up to 5,000 fans at sporting and cultural events. The price of admission: follow strict rules and keep quiet. https://t.co/7MKFRE21eI

— The New York Times (@nytimes) September 14, 2020

Breaking News: Japan’s governing party has all but assured that Yoshihide Suga will become prime minister. Here’s what we know about Shinzo Abe’s successor. https://t.co/oBpcGKwWwX

— The New York Times (@nytimes) September 14, 2020

Japan’s new cabinet looks a lot like its old (male-dominated) cabinet https://t.co/CPrlBf7ZVO

— The Washington Post (@washingtonpost) September 16, 2020

The architects of Mario reflect on 35 years and the evolution of the franchise’s most iconic jump https://t.co/zVY6qXomRN

— The Washington Post (@washingtonpost) September 14, 2020

Japan ruling party elects Yoshihide Suga to succeed Shinzo Abe as prime minister https://t.co/pDsZ65Tud6

— The Washington Post (@washingtonpost) September 14, 2020

Japan’s new prime minister, Yoshihide Suga, will have a challenge ahead of him in how he deals with his relationship with both the U.S. and China, especially as tensions between the two escalate #WSJWhatsNow pic.twitter.com/uzHz0Y3vF4

— The Wall Street Journal (@WSJ) September 16, 2020

The era of Japan's Shinzo Abe is over, with Yoshihide Suga elected prime minister in the first leadership change since 2012 https://t.co/ZZGxpsQFjN

— The Wall Street Journal (@WSJ) September 16, 2020

Suga was elected Japan’s prime minister, as the country seeks to emerge from the coronavirus pandemic and navigate rising U.S.-China tensions https://t.co/NTdZh5yTmm

— The Wall Street Journal (@WSJ) September 16, 2020

On trial in Tokyo, Greg Kelly, Carlos Ghosn's former confidant at Nissan, made clear that, far from blaming his former boss for his troubles, he would serve as a spokesman for the good he believed Ghosn brought to Japan https://t.co/JBZnbyp8Ye

— The Wall Street Journal (@WSJ) September 15, 2020

Greg Kelly, the former Nissan executive charged with helping hide Carlos Ghosn’s compensation, pleaded not guilty at the opening of his trial in Tokyo #WSJWhatsNow pic.twitter.com/a2ZQHprAKC

— The Wall Street Journal (@WSJ) September 15, 2020

Heard on the Street: Japan’s incoming prime minister may pursue many of the same policies as his predecessor, but there are opportunities for serious improvements https://t.co/T7SVotd8PC

— The Wall Street Journal (@WSJ) September 15, 2020

Former Nissan executive Greg Kelly pleaded not guilty to helping Carlos Ghosn hide compensation as his trial gets under way in Tokyo https://t.co/i9RWIQtTqF

— The Wall Street Journal (@WSJ) September 15, 2020

Naomi Osaka won the U.S. Open women’s title—and made a simple statement of protest that will be long remembered, writes @jasongay https://t.co/pmg3QuM3gA

— The Wall Street Journal (@WSJ) September 14, 2020

Before he got Japan’s top government job officially, Yoshihide Suga was known as a “shadow” prime minister and right-hand man to his long-serving predecessor. https://t.co/LOUDGUTU0G

— Los Angeles Times (@latimes) September 16, 2020

Livestock ship carrying 42 crew sinks off Japan’s coast https://t.co/ZvP6uD4lGn

— AJC (@ajc) September 3, 2020

Japan PM Shinzo Abe resigning for health reasons https://t.co/cEG9KBeHSh

— AJC (@ajc) August 28, 2020

BREAKING: Japan floods leave up to 34 dead, many at nursing homes https://t.co/qkE27IPOle

— AJC (@ajc) July 5, 2020

#BREAKING: Japan’s PM says IOC has agreed to delay Olympics for one year. https://t.co/URu4XeHgHr pic.twitter.com/qtpC3CFjKl

— AJC (@ajc) March 24, 2020

Yoshihide Suga was elected as the new head of Japan’s ruling party on Monday, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/ktz8wEqcBm

— The Boston Globe (@BostonGlobe) September 14, 2020

Philly activists help launch American-style capitalist attack in corporate Japan https://t.co/rLo6cqFZEH

— The Philadelphia Inquirer (@PhillyInquirer) February 17, 2020

Several dozen aging U.S. veterans will gather on a battleship in Hawaii's Pearl Harbor next month to mark the 75th anniversary of Japan’s surrender in World War II, even if it means the vulnerable group may be risking their lives again amid a pandemic. https://t.co/43Z2CixhDt

— Chicago Sun-Times (@Suntimes) August 24, 2020

The sudden rise in the number of virus cases in Tokyo and the government’s strong actions immediately after the Olympic postponement have raised questions in parliament and among citizens about whether Japan understated the extent of the outbreak.https://t.co/mrhdXESYtQ

— Chicago Sun-Times (@Suntimes) March 30, 2020

In Japan, there are 13.1 hospital beds for every 1,000 people.

In the U.S., there are just 2.9 hospital beds per 1,000 people.

“If tens of thousands become sick at once, people will simply not receive the care that they need." https://t.co/8fcjncxyu3

— Chicago Sun-Times (@Suntimes) March 15, 2020

If the coronavirus threat continues, the games could be postponed until later in 2020, a statement from Japan’s Olympic minister implied Tuesday. https://t.co/eAz25dgjVP

— Chicago Sun-Times (@Suntimes) March 4, 2020

Trump downplays virus, attacks Biden, Japan's leader steps down and college towns struggle without students https://t.co/lw0Dr1EyvA

— St. Louis Post-Dispatch (@stltoday) August 28, 2020

A sudden rise in virus cases in Tokyo has raised questions about whether Japan understated the extent of its outbreak and delayed enforcement of social distancing measures while clinging to hopes that the Olympics would start on July 24 as scheduled. https://t.co/cUlvMs8kDE

— Star Tribune (@StarTribune) March 30, 2020

"I think we have to hold the games at any cost,” Japan's Olympic minister Seiko Hashimoto said Tuesday. “I want to concentrate all our efforts on measures against the coronavirus." https://t.co/or03jJxefU

— Des Moines Register (@DMRegister) September 9, 2020

On this date in 1945, the Enola Gay dropped an atomic bomb on Hiroshima, Japan. About 70,000 people were killed instantly by the explosion, which had a radius of around a mile. As many as 140,000 people ultimately died from the blast. https://t.co/A1fFWJzgxd

— Des Moines Register (@DMRegister) August 6, 2020

The @uiowa said it was canceling exchange programs in Japan "due to concerns about the ability of the host institutions to provide adequate health and safety infrastructure should the situation with COVID-19 deteriorate." https://t.co/35scIb1qfE

— Des Moines Register (@DMRegister) March 4, 2020

A talented photographer is capturing some amazing closeups of tiny creatures, a sunflower maze has been planted near the Fukushima nuclear disaster site in Japan to help absorb radiation, wolverines have returned to Mount Rainier National Park in… https://t.co/vN4ydsWL8S

— Omaha World-Herald (@OWHnews) August 21, 2020

Pounding rain and flooding battered large areas of Japan's main island, swelling rivers and destroying houses and roads. At least 58 people have died. https://t.co/ZbfLr5TUdU

— Omaha World-Herald (@OWHnews) July 8, 2020

Warren Jorgenson witnessed the attack on Manila at the outset of WWII. He was wounded just before the fall of Corregidor, endured a “hell ship” journey to Japan and spent 3 years as a POW. He died June 1 after a battle with #COVID19. More from @SteveLiewer https://t.co/1jtetAVA5P

— Omaha World-Herald (@OWHnews) June 14, 2020

Japanese Prime Minister Shinzo Abe and his Cabinet resigned, clearing the way for his successor to take over after parliamentary confirmation later Wednesday. https://t.co/6H3jIjHuX2

— The Denver Post (@denverpost) September 16, 2020

Naomi Osaka, a professional tennis player from Japan, wore an Elijah McClain face mask when she took the court Wednesday at the U.S. Open in New York City. https://t.co/ChVBRZsIeX

— The Denver Post (@denverpost) September 3, 2020

Other coronavirus hot spots like China, Iran, Japan, South Korea, Italy and western Washington are all located within similar latitudes to Colorado. https://t.co/UXIicIvzCT

— The Denver Post (@denverpost) March 17, 2020

Who is Japan's "quiet" new leader, and how will he work with Donald Trump, or Joe Biden? https://t.co/9Mr0AWxA58

— CBS News (@CBSNews) September 16, 2020

Yoshihide Suga has been elected Japan's new Prime Minister following a vote in the country's Parliament on Wednesday, confirming the former cardboard factory worker and farmer's son as leader of the world's third largest economy. https://t.co/oKi8HXbMaJ

— CNN International (@cnni) September 16, 2020

Japan's next Prime Minister?

Yoshihide Suga was voted in as the new leader of the ruling Liberal Democratic Party, securing about 70% of the votes, paving the way for the 71-year-old to become PM in a parliamentary vote on Wednesday https://t.co/YD47AGsdOr

— CNN International (@cnni) September 14, 2020

Yoshihide Suga elected as the new head of Japan’s ruling party, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/V5tVxAc9lY

— ABC News (@ABC) September 14, 2020

NEW: Yoshihide Suga set to become Japan's new Prime Minister after PM Abe announced last month he was resigning due to health issues. https://t.co/OCsXm9XgZa

— NBC News (@NBCNews) September 14, 2020

Five takeaways from Japanese Prime Minister Suga’s new cabinet https://t.co/oiXofdFX6b

— Bloomberg Politics (@bpolitics) September 16, 2020

JUST IN: Japan’s parliament elects Yoshihide Suga as new prime minister https://t.co/cXftEY3Zvm

— Bloomberg Politics (@bpolitics) September 16, 2020

BREAKING: Japan's Yoshihide Suga is set to become the country's next prime minister after being elected leader of the ruling Liberal Democratic Party by an overwhelming majority https://t.co/fxh48gCd1z pic.twitter.com/8gVxNDqb2d

— Bloomberg Politics (@bpolitics) September 14, 2020

The front-runner to become Japan’s next prime minister repeated his calls for lower mobile phone fees ahead of elections this week https://t.co/g7ezqpzKmz

— Bloomberg Politics (@bpolitics) September 13, 2020

Yoshihide Suga, the front-runner to become Japan’s next premier, emphasizes the importance of the nation’s alliance with the U.S. https://t.co/OG8p4Z8nxu

— Bloomberg Politics (@bpolitics) September 13, 2020

Yoshihide Suga is a patient man https://t.co/EAdjqoh2qC

— Bloomberg Politics (@bpolitics) September 11, 2020

Yoshihide Suga, the leading candidate to become Japan’s next leader, says he sees no sales tax hike in the next 10 Years https://t.co/qAkoEtQPXK

— Bloomberg Politics (@bpolitics) September 11, 2020

The conservative majority Liberal Democratic Party (LDP) of Japan elected departing Japanese Prime Minister Abe Shinzo’s chief cabinet secretary, Suga Yoshihide, its president on Monday. https://t.co/DbbuiLrJ7x

— Breitbart News (@BreitbartNews) September 15, 2020

What’s Next for the U.S.–Japan ‘Special Relationship’ | https://t.co/zPPEQrWns2 via @ArthurLHerman pic.twitter.com/SZeCtZqzE2

— National Review (@NRO) August 27, 2020

Japan’s Economy Shrinks at a Record 7.8 Percent https://t.co/WW84e5TOyE pic.twitter.com/T5AvDpwE2p

— National Review (@NRO) August 18, 2020

A Lesson from Japan’s Fight against Coronavirus: Masks Help | https://t.co/qqCQLmQYZf via Linda Halderman pic.twitter.com/g3pUus7H2l

— National Review (@NRO) March 31, 2020

“Washington must do all that it can to support Japan’s next captain as he assumes the tiller to maintain a steady course.” https://t.co/5EM0E1pbtN

— Heritage Foundation (@Heritage) September 2, 2020

https://twitter.com/HudsonInstitute/status/1273284986150563841
https://twitter.com/ColumbiaSIPA/status/1304085453952483328

Abe left Japan's Liberal Democratic Party in a good position politically, thus his successor will step into the prime minister’s office with a strong legislative foundation from which to govern, writes @sheilasmithcfr https://t.co/c5h4a2iKCo

— Council on Foreign Relations (@CFR_org) September 11, 2020

In @ForeignPolicy, @sheilasmithcfr highlights three challenges Japan's next prime minister will face: https://t.co/YnAZhrdwll

— Council on Foreign Relations (@CFR_org) September 8, 2020

On this day in 1945, Japan signed a formal surrender, officially ending World War II. Trace the last days of Imperial Japan in this timeline. https://t.co/OvjDVIgcBR

— Council on Foreign Relations (@CFR_org) September 2, 2020

Today marks 75 years since the Allied occupation of Japan began, under which the country's new constitution was created.

Today, Japan is debating whether to amend that war-renouncing constitution for the first time. Here's what that could mean. https://t.co/ViUQjITaZu pic.twitter.com/JcXPxmHEeE

— Council on Foreign Relations (@CFR_org) August 31, 2020

The 2020 Summer Olympics in Tokyo have been postponed, but Japan is still working around the clock to preserve them. Is it worth it?

— Council on Foreign Relations (@CFR_org) July 24, 2020

Japan has escaped the high COVID-19 infection levels seen elsewhere, but its economy has still been hit hard. What can Suga do?https://t.co/jzC9n4tck7

— Foreign Policy (@ForeignPolicy) September 15, 2020

When it comes to Japan’s more muscular approach to foreign policy, Suga may not be Abe’s most aggressive steward, FP's @JackDetsch writes.https://t.co/UQ0wRAu0wF

— Foreign Policy (@ForeignPolicy) September 15, 2020

Incoming Japanese Prime Minister Yoshihide Suga has already made clear that his goal is stability, not innovation.https://t.co/LzxWZlgpkp

— Foreign Policy (@ForeignPolicy) September 14, 2020

Shinzo Abe’s successor will be chiefly preoccupied with three challenges: Japan’s coronavirus pandemic-related economic fallout, national security, and its rapidly-aging population, Sheila A. Smith writes. https://t.co/Hwgjq5cdMP

— Foreign Policy (@ForeignPolicy) September 12, 2020

A relationship that was near its peak in 2012 is now at a nadir since Japan and South Korea normalized their diplomatic relationship in 1965, S. Nathan Park writes.https://t.co/AhhgcvRTCz

— Foreign Policy (@ForeignPolicy) September 9, 2020

At the core of Abe’s foreign policy was the alliance with the United States, Michael Auslin writes. The great question for Japan, of course, is who succeeds Abe and what will they do with his policies? https://t.co/1A76azxpGy

— Foreign Policy (@ForeignPolicy) August 31, 2020

Last year, William Sposato wrote about Japanese Prime Minister Shinzo Abe, and how his cherished personal goal of shedding the pacifist nature of Japan’s postwar constitution seemed just out of reach. From our archives:https://t.co/EdU0ixwXG9

— Foreign Policy (@ForeignPolicy) August 28, 2020

For the past 75 years, the American postwar military occupation of Japan has served as a model for how the U.S. might dominate global battlefields. But this precedent is far more fraught than it appears, writes Marc Gallicchio https://t.co/lcCzzEsARi

— Foreign Policy (@ForeignPolicy) August 16, 2020

Japan’s cancellation of the Aegis Ashore ballistic missile defense system, while primarily motivated by the high cost, was also inspired by opposition by community members who feared the health effects of the weapon, Jeffrey W. Hornung writes. https://t.co/F4LaosW7Pa

— Foreign Policy (@ForeignPolicy) July 2, 2020

Japan’s labor shortage forced the country to increase its immigration numbers, showing that it’s possible to accept immigrants without political backlash.https://t.co/5SvQ5QzIBr

— Foreign Policy (@ForeignPolicy) June 25, 2020

In Japan, South Korea and Taiwan, state-led nuclear energy development took place during the political dominance of conservative parties. As liberal parties begin taking control in these nations, anti-nuclear sentiment is rising. https://t.co/NGZmaNoZGp

— Foreign Policy (@ForeignPolicy) June 20, 2020

Yukio Okamoto died from complications due to the coronavirus. His death is not only a personal tragedy, but also a huge loss to the future of U.S.-Japan relations. https://t.co/K0L8ucWWsi

— Foreign Policy (@ForeignPolicy) May 22, 2020

With among the lowest death rates in the world, a medical system that has avoided an overloading crisis, and a declining number of cases, everything seems to be going oddly right in Japan.https://t.co/aoJn7fjP2d

— Foreign Policy (@ForeignPolicy) May 15, 2020

Japan's coronavirus success remains a mystery.https://t.co/aoJn7fjP2d

— Foreign Policy (@ForeignPolicy) May 14, 2020

Japan will soon discover whether its workaholic company employees will now see that their moral duty is to stay home.https://t.co/ADGB33Qu4n

— Foreign Policy (@ForeignPolicy) April 10, 2020

Japanese ruling party leader Yoshihide Suga was elected prime minister in a parliamentary vote Wednesday, becoming the country’s first new premier in nearly eight years https://t.co/E6qgh4kt88

— TIME (@TIME) September 16, 2020

"It’s hard to call Abe a transformational leader,” writes @ianbremmer. “But just because Abe failed to be a transformative politician hasn’t made him a failed one.” https://t.co/s9LSpBa3c6

— TIME (@TIME) September 11, 2020

Japanese Prime Minister Shinzo Abe’s successor must deal with a stricken economy, an increasingly bellicose China and North Korea, an unpredictable White House and a ticking demographic time bomb https://t.co/GMiaJBAyrr

— TIME (@TIME) September 8, 2020

Japanese Prime Minister Shinzo Abe and his Cabinet resigned, clearing the way for his successor to take over after parliamentary confirmation later Wednesday https://t.co/ORJAXUD9Yn

— POLITICO (@politico) September 16, 2020

Japan's governing party picks Yoshihide Suga as next prime minister https://t.co/0FAIen2y5q pic.twitter.com/sTFpyDtI9w

— The Hill (@thehill) September 16, 2020

Japan's Olympics minister: "I think we have to go ahead with the Games" https://t.co/froF2TG8Oc pic.twitter.com/6kklbN4F5d

— The Hill (@thehill) September 8, 2020

Recent articles about Japan 日本関連英文記事 Vol.2

All the below tweets are in English.

Japan's economy minister instructed by new PM to take steps without hesitation https://t.co/SiCJ1ZTnFU pic.twitter.com/lFsQdM8851

— Reuters (@Reuters) September 17, 2020

Japan's reappointed finance minister Aso says will prod regional banks to pursue reforms https://t.co/WAZp0v2BNV pic.twitter.com/4WuhopXYo3

— Reuters (@Reuters) September 17, 2020

BOJ to hold fire, signal resolve to work closely with Suga's new cabinet https://t.co/yqw5rAjbSZ pic.twitter.com/dTr8OriSFV

— Reuters (@Reuters) September 17, 2020

Japan's longest-serving prime minister Shinzo Abe left office amid applause before his longtime aide Yoshihide Suga was voted prime minister by parliament https://t.co/hKCJX4sWIZ pic.twitter.com/VYrTnrLJJp

— Reuters (@Reuters) September 16, 2020

Japan’s new Prime Minister Yoshihide Suga said he would stick with his former boss’ 'Abenomics' growth policies while pushing reforms https://t.co/PFUWnSF9bC pic.twitter.com/4tlbtLOFFM

— Reuters (@Reuters) September 16, 2020

From @Breakingviews: Japan has a new prime minister after nearly eight years. Yoshihide Suga, the tight-lipped technocrat, will need to shed some of his stern demeanor to lead the country out of recession, says @petesweeneypro pic.twitter.com/eWji7cC9sE

— Reuters (@Reuters) September 16, 2020

Telefonica partners with Japan's Rakuten to develop open 5G network https://t.co/FQtFzQyIMf pic.twitter.com/BNsFRXUpkh

— Reuters (@Reuters) September 16, 2020

China says it hopes Japan will not develop official ties with Taiwan https://t.co/S8aWZPP07W pic.twitter.com/IxK1g8HGVh

— Reuters (@Reuters) September 16, 2020

Japan’s Yoshihide Suga was voted prime minister by parliament to become the country’s first new leader in nearly eight years, appointing a new cabinet that kept about half of the familiar faces from predecessor Shinzo Abe’s lineup https://t.co/e9YG3w6TL6

— Reuters (@Reuters) September 16, 2020

Japan's exports extend double-digit declines as pandemic hits demand https://t.co/e3kNHS0rOJ pic.twitter.com/wJKcX7OBE1

— Reuters (@Reuters) September 16, 2020

Japan defence minister Kono to become internal affairs min in new cabinet: Kyodo https://t.co/PH4IqpQmUo pic.twitter.com/C75zhyYPEc

— Reuters (@Reuters) September 15, 2020

After sweeping party poll, Japan's Suga faces tricky call on snap election https://t.co/hXKdA0zFZb pic.twitter.com/yYvm4vUcQP

— Reuters (@Reuters) September 15, 2020

Japan's Aso says should consider early dissolution of parliament https://t.co/PI5GGsIn5T pic.twitter.com/0UQwnnEols

— Reuters (@Reuters) September 15, 2020

Japan's new leadership agenda could make jobs a bigger BOJ priority https://t.co/jfL67MCYVv pic.twitter.com/DjgE1y38Dv

— Reuters (@Reuters) September 15, 2020

Japan ruling party head Suga preparing cabinet, continuity in foreground https://t.co/4WcznGiSY5 pic.twitter.com/2FJqlXeXJ1

— Reuters (@Reuters) September 15, 2020

Japan health minister Kato likely to replace Suga as chief cabinet secretary: Nippon TV https://t.co/ErdsJudoE6 pic.twitter.com/LDsrJGTs6n

— Reuters (@Reuters) September 15, 2020

From @Breakingviews: Nvidia will buy UK-based chip designer Arm from Japan’s SoftBank Group and its growth will depend on winning over many of Arm’s customers like Intel, which compete with Nvidia, as well as anti-trust regulators around the world, @LiamWardProud says pic.twitter.com/kmcEjAooNu

— Reuters (@Reuters) September 15, 2020

United Airlines to close Japan's Narita hub, affecting 270 jobs: NHK https://t.co/OqmpLBQHfu pic.twitter.com/x2n3OOKtWU

— Reuters (@Reuters) September 14, 2020

Japan's Suga wins ruling party leadership race to replace Abe https://t.co/zs7oL16itL pic.twitter.com/zsSHbVTY38

— Reuters (@Reuters) September 14, 2020

Japan’s Yoshihide Suga wins ruling party leadership election, paving the way for him to become prime minister in a parliamentary vote this week https://t.co/YRwm9K9Int pic.twitter.com/3v3Mf1JIOr

— Reuters (@Reuters) September 14, 2020

Japan's next prime minister as a boy: good in sports, 'stiff' as actor https://t.co/92zlCQfyYQ pic.twitter.com/3UKmjxhTkO

— Reuters (@Reuters) September 14, 2020

Factbox: Japan next premier's hometown: demographic challenges by the numbers https://t.co/1QTxKQCVxG pic.twitter.com/uYzx0b55Te

— Reuters (@Reuters) September 14, 2020

Japan's Suga says no limit to bonds government can issue https://t.co/3UiYqHO5yH pic.twitter.com/pMLXlXn8Aa

— Reuters (@Reuters) September 13, 2020

Japan's Suga says no limit to bonds government can issue https://t.co/47gMZ8iSS1 pic.twitter.com/1Z6Zr4GW3H

— Reuters (@Reuters) September 13, 2020

Osaka 'a Jesse Owens of Japan' for racial injustice stand https://t.co/imj7cYQq6T pic.twitter.com/sz0sVBx8j1

— Reuters (@Reuters) September 12, 2020

Hip hop hooray for Japan's next PM with hometown T-shirt shout-out https://t.co/AoHablSyRd pic.twitter.com/PDxTZiwS7N

— Reuters (@Reuters) September 12, 2020

Japan's Suga, likely next PM, says ready to top up payouts to ease COVID-19 pain https://t.co/3I5JpaJRM1 pic.twitter.com/271DkXf312

— Reuters (@Reuters) September 12, 2020

Japan's Suga seeks solid communications with Asian neighbors https://t.co/dTL3DCFEJK pic.twitter.com/1iEUL3WkjB

— Reuters (@Reuters) September 12, 2020

Tiffany gets regulatory nod from Japan, Mexico for troubled LVMH deal https://t.co/VqNr9haIIm pic.twitter.com/Dn4jrGvVPh

— Reuters (@Reuters) September 11, 2020

Abe plan for land-attack counterpunch could mark major military shift for Japan https://t.co/N3f7XG0xhq pic.twitter.com/CFgEMjmg4A

— Reuters (@Reuters) September 11, 2020

UK and Japan strike Britain's first post-Brexit trade deal https://t.co/KTn04NK77g pic.twitter.com/BxaqsrdWbx

— Reuters (@Reuters) September 11, 2020

Japan's new government should focus on response to coronavirus, digitalization: Reuters poll https://t.co/1rmBToSQ86 pic.twitter.com/2PacSUBneb

— Reuters (@Reuters) September 11, 2020

Japan foreign minister says aims to reach broad agreement on UK trade deal Friday https://t.co/lIXpIorFrb pic.twitter.com/BvA9E7BOZl

— Reuters (@Reuters) September 11, 2020

Japan firms plan to cut capex by 6.8% this fiscal year: survey https://t.co/cjgobzhKJO pic.twitter.com/yQzvX3gUgg

— Reuters (@Reuters) September 11, 2020

Japan's Suga: Will have to call for sales tax hike in future https://t.co/4P8FLYxHCw pic.twitter.com/SRlShwBXgo

— Reuters (@Reuters) September 10, 2020

Stuck at home for weeks while Japan was under a state of emergency due to the coronavirus, renowned Japanese Bunraku puppet master Kanjuro Kiritake, all his performances canceled for months, was stricken with deep anxiety https://t.co/ITent24Oip

— Reuters (@Reuters) September 10, 2020

Yoshihide Suga, on course to become Japan’s next prime minister, said he would maintain incumbent premier Shinzo Abe’s policy prioritizing economic growth over efforts to fix the country’s tattered finances https://t.co/n0731rDKOc

— Reuters (@Reuters) September 9, 2020

Exclusive: Japan ruling coalition partner Komeito indicates it does not want snap election https://t.co/oEcSPCorwu pic.twitter.com/fuompQDij9

— Reuters (@Reuters) September 9, 2020

Japan's households, firms keep hoarding cash at record pace as COVID-19 strains broaden https://t.co/rLbJKNkW0A pic.twitter.com/pLs5P2Re3o

— Reuters (@Reuters) September 9, 2020

Japan's Suga in pole position for PM as debate kicks off https://t.co/AWXlIX2ibM pic.twitter.com/H5UMOlUlFr

— Reuters (@Reuters) September 9, 2020

Japan's Suga says important to cover fertility treatment by national insurance https://t.co/8xeoz2tlgy pic.twitter.com/8XDyhPHQJa

— Reuters (@Reuters) September 9, 2020

Japan’s economy shrank by over 28% in the second quarter as the global crisis had businesses struggling more than initially thought, underscoring the daunting task the new prime minister faces in averting a steeper recession https://t.co/WGdKT6Sbrd pic.twitter.com/fi2eOCJQ2X

— Reuters (@Reuters) September 8, 2020

Japan's Chief Cabinet Secretary Yoshihide Suga, a frontrunner to succeed Prime Minister Shinzo Abe, could call a snap election to solidify his political grip if he becomes the country's next premier https://t.co/mN5FBhmnnE pic.twitter.com/pH5vQRfS81

— Reuters (@Reuters) September 8, 2020

Tokyo 2020 Olympics organisers have not extended sponsors’ contracts set to expire at the end of the year, sources said, leaving some questioning whether to continue after COVID-19 forced a delay of the world’s largest sporting event https://t.co/e51BZ3IRaD

— Reuters (@Reuters) September 8, 2020

Factbox: Continuity and reforms: Japan PM hopeful Suga's key policies https://t.co/Gr20nDT77C pic.twitter.com/NXxZB5a5tP

— Reuters (@Reuters) September 8, 2020

Japan defence chief Kono expects to be prime minister one day, but backs Suga to succeed Abe https://t.co/DD2zcP0akQ pic.twitter.com/UtWRxXKs1T

— Reuters (@Reuters) September 3, 2020

Japan LDP heavyweight Kishida: Frank discussions needed with U.S. over defence burden https://t.co/7Hq6jQl89v pic.twitter.com/bgteKbqja5

— Reuters (@Reuters) September 2, 2020

Japan former foreign minister Kishida announces candidacy to succeed PM Abe https://t.co/KAJ37IIfMb pic.twitter.com/qMr56YBcHi

— Reuters (@Reuters) September 1, 2020

Japan's PM candidate Kishida cautious about cutting sales tax https://t.co/c2rpGAR3j5 pic.twitter.com/eQ4ijGJ9LI

— Reuters (@Reuters) August 31, 2020

Japan Defence Minister Kono says still undecided on run for ruling party leadership https://t.co/RIOCsS4eR8 pic.twitter.com/mL7SYNzqWs

— Reuters (@Reuters) September 1, 2020

Ex-defence minister Ishiba is people's choice for next Japan PM: polls https://t.co/vz2wwRC27L pic.twitter.com/FDUz78EpgK

— Reuters (@Reuters) August 31, 2020

Japan's Koizumi won't seek to succeed Abe as PM, would back Kono – NHK https://t.co/qkqUEYeUkN pic.twitter.com/sD38jEwhIV

— Reuters (@Reuters) August 30, 2020

Japan’s Sumitomo Corp. exits U.S. shale gas industry. via @Reuters https://t.co/wowqaMYt5d

— IEEFA_AsiaPacific (@IEEFA_AsiaPac) September 10, 2020

BREAKING: Yoshihide Suga has been formally elected Japan’s prime minister in a parliamentary vote. Suga was long the right-hand man to his predecessor, Shinzo Abe, who was Japan’s longest-serving prime minister. https://t.co/p6Ux2TPe3w

— The Associated Press (@AP) September 16, 2020

Yoshihide Suga has been elected as the new head of Japan’s ruling party, virtually guaranteeing him parliamentary election as the country’s next prime minister. https://t.co/Qjb7UPKAPp

— The Associated Press (@AP) September 14, 2020

Japanese prime minister hopeful Yoshihide Suga says he lacks the kind of diplomatic skills that outgoing leader Shinzo Abe has, including Abe's personal friendship with President Trump, and that he will need his assistance if he assumes the top job. https://t.co/Z176gjbjIN

— The Associated Press (@AP) September 12, 2020

https://twitter.com/AFP/status/1306237603637874688

#UPDATES Japan's parliament elects Yoshihide Suga prime minister, with the former chief cabinet secretary expected to stick closely to policies championed by Shinzo Abe during his record-breaking tenure https://t.co/BsfvhxSd6V pic.twitter.com/YXORmDXKA9

— AFP news agency (@AFP) September 16, 2020

Japan's parliament votes today for the country's next prime minister, with powerful cabinet secretary Yoshihide Suga all but assured the top jobhttps://t.co/8wZhfDupzw pic.twitter.com/ULPxi84Riw

— AFP news agency (@AFP) September 16, 2020

VIDEO: Japan's chief cabinet secretary Yoshihide Suga pledges a continuation of Shinzo Abe's policies as he is elected as the ruling party's new leader, making him all but certain to become the country's next prime minister pic.twitter.com/Utn5ZAoruf

— AFP news agency (@AFP) September 15, 2020

VIDEO: Japan ruling party elects Yoshihide Suga as PM successor.

The vote makes Suga all but certain to replace Shinzo Abe as the country's next prime minister pic.twitter.com/l9dfDW0Wee

— AFP news agency (@AFP) September 14, 2020

Japan's ruling party votes today for its next leader, with top government adviser Yoshihide Suga all but certain to win and replace Shinzo Abe as the country's new prime ministerhttps://t.co/yXRA6YPdmV pic.twitter.com/wRzMpvdWNV

— AFP news agency (@AFP) September 14, 2020

Japan's Yoshihide Suga to formally take up PM job, announce 'continuity' cabinet https://t.co/lCq86q9598 pic.twitter.com/8TVMcOF1tS

— FRANCE 24 (@FRANCE24) September 16, 2020

Japan's Yoshihide Suga wins leadership race to succeed outgoing PM Shinzo Abe https://t.co/XJCoFr5ful pic.twitter.com/wS6Dbftjiu

— FRANCE 24 (@FRANCE24) September 14, 2020

https://twitter.com/France24_fr/status/1305432334355902464
https://twitter.com/France24_en/status/1305441224132898817
https://twitter.com/i_montaigneEN/status/1305157795155714049

Concerns about the US’ readiness and ability to fulfill its security commitments have led Japan to enact security reforms to enhance its value as an ally while moving toward a more autonomous defense posture to prepare for the worst-case scenario.

➡️ https://t.co/CPn7pN2wRD pic.twitter.com/9aIPHUl32E

— IFRI (@IFRI_) July 24, 2020

In Japan, language is an integral part of a vertical society in which submission is a virtue. Japanese has different words for addressing a superior, a colleague or a sibling, which signal their place in society.https://t.co/1huvL32KBl

— Le Monde diplomatique in English (@LMdiplo) September 13, 2020

Years after the tsunami that swept northeast Japan, towns are being rebuilt. But will their inhabitants return, and should they? Fukushima’s toxic legacy will last for decades.

(September: the longer view.)https://t.co/MD2pzQ0djt

— Le Monde diplomatique in English (@LMdiplo) September 13, 2020

Yoshihide Suga won Japan's ruling party leadership race, virtually guaranteed to become the country's next prime minister. https://t.co/XLmF1dJ6ss

— DW News (@dwnews) September 14, 2020

Recent articles about Japan (mainly on new cabinet) 主に新内閣発足についての日本関連英文記事 Vol.1

All the below tweets are in English.

日本関連ツイートを拾うことは通常どおり特にしない予定でしたが、Reuters社を中心に以前よりは数が増えている感触があるので、前回投稿分以降の日付のものを中心にざぁっとですが拾ってみました。３回に分けて投稿します。
While I have not intended to collect news articles mainly on Japan’s new cabinet, I have come to confirm that there are more articles – mainly by Reuters – related to such issues than before as I have thought. That is why I collected roughly and posted here mainly tweets after the last post (Sep 8). This is the first of the three posts this time.

Hitachi to pull plug on north Wales nuclear power station https://t.co/9UiBT8ivbX

— The Guardian (@guardian) September 15, 2020

A Japan trade deal is little consolation if Britain is locked out of the EU https://t.co/VFXzXABLgg

— The Guardian (@guardian) September 13, 2020

Japan trade deal is small beer – but a welcome distraction https://t.co/PYes0nZkXr

— The Guardian (@guardian) September 11, 2020

UK government hails 'historic' trade deal with Japan https://t.co/tCu1vE1VHZ

— The Guardian (@guardian) September 11, 2020

Tokyo Olympics must be held at 'any cost', says Japanese minister https://t.co/s3iKj7upPC

— The Guardian (@guardian) September 8, 2020

Yoshihide Suga emerging as favourite to become Japan's prime minister https://t.co/kvdxwSftOD

— The Guardian (@guardian) September 1, 2020

#FPCJ #japannews @guardian
Yoshihide Suga to be Japan's prime minister after winning party vote https://t.co/NvynYefFBG

— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 15, 2020

#FPCJ #japannews @guardian
Yoshihide Suga: the farmer's son set to be Japan's next PM https://t.co/LNojbwYdMz

— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 14, 2020

Yoshihide Suga was elected Japan’s new prime minister in a parliamentary vote, following the resignation of Shinzo Abe https://t.co/3topdlCjap

— The Telegraph (@Telegraph) September 16, 2020

Who is Yoshihide Suga, the new Prime Minister of Japan? https://t.co/s885naHuXp

— The Independent (@Independent) September 16, 2020

Yoshihide Suga formally elected as Japan’s new prime minister https://t.co/3JhhviQCOW

— The Independent (@Independent) September 16, 2020

Yoshihide Suga: The unexpected rise of Japan’s new prime minister https://t.co/VbOcBegU78

— BBC News (World) (@BBCWorld) September 16, 2020

Yoshihide Suga elected Japan's new prime minster succeeding Shinzo Abe https://t.co/ifNL6ETIOn

— BBC News (World) (@BBCWorld) September 16, 2020

Yoshihide Suga: The strawberry farmer's son on track to be Japan's PM https://t.co/QrvbOikYnt

— BBC News (World) (@BBCWorld) September 14, 2020

#FPCJ #japannews @BBCWorld
BBC News – Yoshihide Suga: The strawberry farmer's son on track to be Japan's PM https://t.co/t8t07LBXBr

— Foreign Press Center Japan/フォーリン・プレスセンター (@fpcjpn) September 15, 2020

Japan's new prime minister Yoshihide Suga promises to turn round economy after succeeding Shinzo Abe https://t.co/GR4b8Dk1tf

— SkyNews (@SkyNews) September 16, 2020

Yoshihide Suga is set to become Japan's new prime minister, following the resignation of Shinzo Abe https://t.co/iWjgw5zvB7

— SkyNews (@SkyNews) September 14, 2020

Each year, the Japanese drink enough ready-to-drink coffee to fill Tokyo’s new Olympic Stadium almost to the brim https://t.co/rz81kHc1J0

— The Economist (@TheEconomist) September 16, 2020

Japan's shrinking and ageing population is stoking the demise of rural railway lines https://t.co/pXlPOztwDu

— The Economist (@TheEconomist) September 16, 2020

Suga Yoshihide secured the support of Japan’s ruling Liberal Democratic Party by pledging continuity and stability at a time of crisis https://t.co/pPcvZVPBXe

— The Economist (@TheEconomist) September 15, 2020

Today on “The Intelligence”: Japan’s new prime minister, the state of the World Health Organisation and the great canine schism among Egypt’s clerics https://t.co/xDPKcE3gSE

— The Economist (@TheEconomist) September 15, 2020

If Japan's next prime minister succeeds, it will be thanks in large part to the groundwork laid by Abe Shinzo https://t.co/SALMLrrYPp

— The Economist (@TheEconomist) September 6, 2020

Many have cast Abe Shinzo's resignation as an admission of defeat. But Japan's outgoing prime minister has done a far better job than is commonly acknowledged. Our cover in Asia this week https://t.co/epAEDInipU pic.twitter.com/PnzNEhbBHR

— The Economist (@TheEconomist) September 3, 2020

“It says: ‘Please attack us’,” complains a campaigner against a proposed military base in Japan https://t.co/abFed4jNNm

— The Economist (@TheEconomist) August 15, 2020

#lockdown giving you itchy feet? Over on our #blog, Dr Sonia Favi discusses how in the Tokugawa era, #maps provided a 'virtual' means of exploring and domesticating the Japanese territory, even when physical travel wasn’t possible https://t.co/5Aw3iZidtC @TheJohnRylands @UoMSALC pic.twitter.com/VMnnLZANu8

— JRRI (@JRRIManchester) July 6, 2020

Yoshihide Suga is not your typical Japanese politician and yet the 71-year-old son of a strawberry farmer is about to become Japan's next prime minister | @ErykBagshaw https://t.co/YdxLk4wGgn

— The Sydney Morning Herald (@smh) September 14, 2020

Shinzo Abe's chief cabinet secretary Yoshihide Suga is set to become Japan's next prime minister after winning a mandate to continue his predecessor's domestic and foreign policy | @ErykBagshaw https://t.co/L5ehz7jTpb

— The Sydney Morning Herald (@smh) September 14, 2020

Yoshihide Suga, Japan's Chief Cabinet Secretary and a longtime loyal assistant of outgoing Prime Minister Shinzo Abe, has emerged as a favourite to succeed him in an upcoming internal party vote https://t.co/n1zNdzRRgy

— The Sydney Morning Herald (@smh) September 2, 2020

David Walton and Akimoto Daisuke: The decision by the Turnbull government in 2016 to select a French company to produce Australia’s next generation of submarines over Japan’s tender highlighted the limitations of networks and friendships.https://t.co/HRpQaOGhts

— The Lowy Institute (@LowyInstitute) September 4, 2020

"With Australia seeking ever-closer regional cooperation with Japan these days, it will be interesting to see whether the country’s investors will be unnerved by being caught in Australia’s trade row with China."@Greg__Earl writes for The Interpreter.https://t.co/NWqOT8rfcL

— The Lowy Institute (@LowyInstitute) August 31, 2020

Abe aimed to move mountains, setting Japan high goals for the future | Purnendra Jain https://t.co/vynrzxabC2

— The Lowy Institute (@LowyInstitute) August 30, 2020

With the Indo-Pacific increasingly a battleground for technological competition, it appears likely that US-China tensions will complicate Japan-ASEAN digital ties.

Elliot Silverberg and Patrick Madaj write for The Interpreter.https://t.co/lKvF8wR7P4

— The Lowy Institute (@LowyInstitute) August 16, 2020

"In a similar address to the Lowy Institute a year ago, @ScottMorrisonMP also praised India and Japan as countries with 'shared values' to Australia."@ConversationEDU https://t.co/iARwXSrBzA

— The Lowy Institute (@LowyInstitute) August 6, 2020

"In a commentary last year written for The Interpreter blog from Australia's Lowy Institute, Layton detailed just how far the Chinese flights stretch the JASDF, and how China has the resources to push Japan to limits it may not be able to reach."@cnni https://t.co/LnI3HSyOxu

— The Lowy Institute (@LowyInstitute) July 30, 2020

"An overwhelming 82 per cent of Australians said they expected Japan to act responsibly in the world. On the same question, the response regarding China was a dismal 23 per cent"

Nonresident Fellow @Rory_Medcalf on Lowy Institute Poll in @FinancialReview https://t.co/0dAWDLfKCd

— The Lowy Institute (@LowyInstitute) July 13, 2020

Beyond Covid, the chance for a broader Australia-Japan relationship | Donna Weeks https://t.co/jWd4qbeuwC

— The Lowy Institute (@LowyInstitute) July 6, 2020

As China rises, does Australia, India, Japan, and the United States have any real prospect of rebalancing relationships in Asia?

Read the latest Lowy Institute Analysis on the Security Quadrilateral Dialogue by Dr Lavina Lee. https://t.co/3rHK0bjip3

— The Lowy Institute (@LowyInstitute) May 22, 2020

Japan: Article 9 conundrum rears its head again | David Walton https://t.co/g3erhFcktW

— The Lowy Institute (@LowyInstitute) February 24, 2020

Japan–South Korea tensions show little sign of easing | Kate Kalinova https://t.co/a5lWZFyghy

— The Lowy Institute (@LowyInstitute) February 17, 2020

#BREAKING Japanese Coastguard has reportedly made the decision to suspend its fulltime search for the 40 people still missing from the livestock ship. https://t.co/5kPFsNszQP pic.twitter.com/v3KPgjWKNA

— nzherald (@nzherald) September 10, 2020

#BREAKING Missing Kiwis: Japan to resume search for crew of livestock ship https://t.co/tAqQjJTgcc pic.twitter.com/YtKCeBkt2z

— nzherald (@nzherald) September 7, 2020

#BREAKING The second person rescued by Japanese coastguard has died. https://t.co/YrzrVGD9Sg pic.twitter.com/G3vTOgyyKc

— nzherald (@nzherald) September 4, 2020

#BREAKING They sent a distress signal at 4.45am NZT off the coast of Japan as the area was hit by a Typhoon. Now the ship has disappeared. https://t.co/UJUmRTrPFY pic.twitter.com/KGDrbXTWTJ

— nzherald (@nzherald) September 2, 2020

Japan's Parliament has elected Yoshihide Suga as prime minister, replacing long-serving leader Shinzo Abe with his right-hand man. https://t.co/i4yQL9llz4

— CBC News (@CBCNews) September 16, 2020

Yoshihide Suga has been elected as the new head of Japan's ruling party, virtually guaranteeing that he will become the country's next prime minister. https://t.co/rqR2DwTZGn

— CBC News (@CBCNews) September 14, 2020

One person in Japan is dead, and at least two are missing in South Korea after a powerful typhoon. https://t.co/f8sxEEjNOw

— CBC News (@CBCNews) September 8, 2020

U.S. authorities have arrested a former Green Beret and his son who are accused of using large boxes to help scurry Nissan chairman Carlos Ghosn out of Japan. https://t.co/UPxjNx3A05

— CBC News (@CBCNews) May 20, 2020

As the coronavirus spreads in Japan, the chief executive of the Tokyo Games said Friday he can't guarantee the postponed Olympics will be staged next year — even with the long delay. https://t.co/V6QqzigJwC

— CBC News (@CBCNews) April 10, 2020

Japan's prime minister says he will declare a state of emergency for seven prefectures, with Japan also launching its largest ever stimulus package. https://t.co/f6SWfrhyQg

— CBC News (@CBCNews) April 7, 2020

The streets of Tokyo remain busy as Japan adopts its own approach to preventing the spread of coronavirus, one that relies on tracing cases and requesting cooperation, not lockdowns. https://t.co/YKNNsYkV4N @sasapetricic

— CBC News (@CBCNews) April 4, 2020

Japan Olympic minister Seiko Hashimoto says the Tokyo Summer Games could be held later in 2020 due to fast-spreading COVID-19. https://t.co/8gEqMSG8cX

— CBC News (@CBCNews) March 3, 2020

Canadian quarantined in Japan with asymptomatic COVID-19 describes comforts during enforced stay. https://t.co/HfOuAh3Jhb pic.twitter.com/y70dRyVzIE

— CBC News (@CBCNews) February 27, 2020

Japan’s Yoshihide Suga poised to win party race, succeed Shinzo Abe as PM https://t.co/XHP4temuFe

— The Globe and Mail (@globeandmail) September 14, 2020

Japan, eyeing Olympics, lines up half-billion doses of COVID-19 vaccine https://t.co/N3ShUXL25O

— The Globe and Mail (@globeandmail) August 28, 2020

Japan says China has used coronavirus to expand territory, influence https://t.co/6vtuc3NY8T

— The Globe and Mail (@globeandmail) July 14, 2020

Japan to end Tokyo’s state of emergency, eyes massive new stimulus https://t.co/2xqo1lBlOs pic.twitter.com/SQsnCVxqFx

— The Globe and Mail (@globeandmail) May 25, 2020

Japan’s Shinzo Abe slammed over ‘stay home’ shutdown tweet https://t.co/ZpaFBQxGOg pic.twitter.com/93TI0ssMk1

— The Globe and Mail (@globeandmail) April 13, 2020

Nearly 40 feared dead as torrential rains continue to ravage southwest Japan https://t.co/6f7TjQpdH8 pic.twitter.com/DRfb2d0pvW

— The Globe and Mail (@globeandmail) July 6, 2020

Japan bracing for dangerously powerful Typhoon Haishen https://t.co/6iorZ3r31N

— The Globe and Mail (@globeandmail) September 4, 2020

Japan’s ruling party urges government to cancel Xi’s visit over new Hong Kong national security law https://t.co/CVKC12xKeB pic.twitter.com/g0Ybpfpp4g

— The Globe and Mail (@globeandmail) July 7, 2020

Japan ignored the usual rules but contained COVID-19. How did it work? https://t.co/dDDSjdHmbe

— National Post (@nationalpost) May 25, 2020

#Breaking: Olympic Games delayed one year after agreement reached with IOC and Japan PM. https://t.co/5AIrozWunM

— Toronto Star (@TorontoStar) March 24, 2020

France フランス Vol.6（pharmaceutical corporations 製薬会社）

All the below links and tweets are in English.

France Vol.15 (pharmaceutical corporations: Sanofi)
France Vol.16 (pharmaceutical corporations: Ipsen, Servier)
France Vol.17 (pharmaceutical corporations)　 Pierre Fabre, LFB Biotechnologies

ツイッター検索で上記5製薬会社各社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

1/ We were honored to host dinner this week to celebrate the closing of the @TakedaPharma acquisition of Shire and to welcome new USAIC Board Members: John Reed of @Sanofi Phillip Larsen of @Bayer and John Orloff of @AlexionPharma pic.twitter.com/W2TOzaJW6i

— USAIC (@USAIC) January 30, 2020

Through research we commissioned with @EIUPerspectives in the US, Japan and Europe, gaps have been uncovered in #cancer care for the aging, and the impact those gaps can have on healthcare systems. Find out more. #WhenCancerGrowsOld

— Sanofi (@sanofi) June 18, 2020

Through research with @TheEconomist in the U.S., Japan and Europe, we’ve uncovered gaps in #cancer care for the aging, and the impact those challenges can have on healthcare systems. Find out more about what we learned. #WhenCancerGrowsOld

— Sanofi (@sanofi) February 10, 2020

#DRG epidemiology report estimates more than 8.5 million diagnosed events of #RSV across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #respiratorysyncytialvirus @sanofi https://t.co/qmI5DN8A8D

— DRG Epidemiology (@DRG_Epi) December 19, 2019

#DRG epidemiology report estimates more than 28 million #influenza events across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #flu #ESCCongress #OurHeartIsInIt @sanofi https://t.co/b9ro3FzMDn

— DRG Epidemiology (@DRG_Epi) September 5, 2019

Currently, more than 190 million people suffer from #allergicrhinitis across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data and forecast trends @DRGinsights @sanofi #WorldAllergyWeek https://t.co/UwFVqRvZUF

— DRG Epidemiology (@DRG_Epi) April 11, 2019

#DRG epidemiology report estimates nearly 30 million #influenza #flu events across the United States, Western Europe and Japan. @DRGinsights @sanofi https://t.co/aMX8ZwAEY0

— DRG Epidemiology (@DRG_Epi) August 22, 2018

J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9

— Aspen Biosciences (@aspenbio) July 19, 2020

.@sanofi, the company that produces #Lantus, had already filed 74 patents for the drug in the US by 2018 – this is 1.5 times more than those in Europe, and almost triple than in Japan. pic.twitter.com/HBjUqpT2NU

— I-MAK (@IMAKglobal) November 8, 2019

How about a deal with @SangamoTx to better exploit protein homeostasis? Hematology is unpartnered @ScienceAtBMS @bmsnews @JoeSzustakowski.
Partners include @sanofi @NovartisScience @pfizer #takeda @GileadSciences @KitePharma @biogen $SGMO $BMY $PFE $NVS $SNY $GILD $BIIB https://t.co/tJzQPwFTgB

— biotech 2050 (@Biotech2050) July 30, 2020

Also underlines the integrated approach championed by the @WHO i.e vaccine(s) alone are not the solution we have to pull together #diagnostics #communityengagement #vectorcontrol & is exactly why we are advocating for a @WorldDengueDay to be officially recognised @sanofi @Takeda https://t.co/NtOGRRTIar

— ISNTD (@ISNTD_Press) July 14, 2020

The key players in Non-Small Cell Lung Cancer #market include @Novartis, @Merck, @LillyPad, Hoffmann-La-@Roche, @Xcovery, @beyondspring26, @OSEIMMUNO, @sanofi, @Takeda, @abbvie and others.

For more detailed information visit: https://t.co/RWk90xqKhl #LungCancer #Cancer

— DelveInsight (@delve_insight) May 12, 2020

#Takeda’s #dengue shot, rival to #Sanofi's #Dengvaxia, hits the mark in massive phase 3 study https://t.co/GlYlVhHlSZ @FiercePharma @TakedaPharma @sanofi #vaccine #denguevirus

— Plexus Ventures (@PlexusVentures) January 30, 2019

Top pharma execs discuss and share #bestpractices of what they're doing to meet the challenges of COVID-19 @LillyPad @JNJNews @Roche @Sanofi @Takeda @IFPMA https://t.co/HngTgXpJtH

— Ogilvy Cambridge (@OgilvyCambridge) March 20, 2020

Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx

— Open Targets (@targetvalidate) June 21, 2019

Global Candida Infections Drugs Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Abbott, Pfizer Inc., Novartis AG, Merck & Co., Inc, Sanofi, Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plchttps://t.co/d7povpUALz #new

— Pharma News (@pharminews) September 8, 2020

Global Prostate Cancer Therapeutics Market Likely to Experience a Tremendous Growth in Near Future|| Johnson & Johnson Services, Inc., Astellas Pharma US, Inc., Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AGhttps://t.co/A1PMeJ5FeY #news #pharma #pharmiweb

— Pharma News (@pharminews) August 5, 2020

Pharmaceutical Technology – #October’s top #news #stories https://t.co/xHDYOFwX6W #UCB #RA | #Novartis #Microsoft | #Sobi #Dova | #Sanofi US #manufacturing | #Alexion #Achillion | #Bavarian Nordic #GSK | #Daiichi #Astellas | #Ipsen #Blueprint | …

— GESDAT GmbH (@GESDAT) November 5, 2019

FiercePharmaAsia—Sanofi's Japan cuts; Big Pharma CEOs' Chinese names; Astellas' ESMO win: https://t.co/RbSO8pbM2i #pharma #regulatory

— Pharma Regulatory (@EURegulatory) October 4, 2019

Immunosuppressants Market Impressive Growth 2019 | GlaxoSmithKline plc, Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Astellas Pharma Inc., Zydus Cadila https://t.co/UgRU3aWvgK pic.twitter.com/zRdA3OAcP7

— ABNewswire (@ABNewswire) September 13, 2019

Global Urinary Drugs Market 2019 – Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG – Honest News 24
https://t.co/kHgcMcepxG

— News SummedUp Kenya (@summedupkenya) July 17, 2019

It's Friday afternoon & time for #WeeklyRoundup Read the full article here: https://t.co/cJ5QMOVX5Z
Companies included: @Amgen @astellas @GSK @MSDInvents @Novartis @Pfizer_Ireland @sanofi @VertexPharma #MarketWatch #ThePMI19 pic.twitter.com/wB4do7MdZK

— The PMI (Pharmaceutical Managers' Institute) (@PharmaMgrsInst) January 25, 2019

Big Pharma – Novartis, Pfizer, Sanofi, Otsuka – has decided to partner, rather than rival, with Alphabet's Verily to accelerate clinical trials. Here's a story I wrote about how Alphabet and Apple's clinical trial strategies differ https://t.co/fpW0j2H6hw https://t.co/6xM4gemxEW

— Hannah Kuchler (@hannahkuchler) May 21, 2019

The deals with Novartis, Otsuka, Pfizer and Sanofi will boost its ecosystem and “could help foster greater scientific discovery” as the pharma companies work on “next-generation research and development programs,” Verily said: https://t.co/h6tD7yJiaf

— FierceBiotech (@FierceBiotech) May 21, 2019

Novartis, Sanofi, Otsuka, and Pfizer will work with Alphabet’s #Verily on its #ProjectBaseline clinical research project https://t.co/kLtditGb31

— pharmaphorum (@pharmaphorum) May 22, 2019

As mentioned earlier, Verily, Google's health care division, is also collaborating with Sanofi, Novartis, Otsuka and Pfizer to help them identify suitable patients for clinical drug trials. #digitalmarketing #optimization #growthhacking https://t.co/X1jXvUzYZu

— MRVSKY (@mrvskypro) December 1, 2019

Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo’s pexidartinib secures speedy FDA review https://t.co/ic5dkzRo5Y

— Endpoints News (@endpts) February 5, 2019

Sanofi, Eisai join Lilly's SCOTUS bid to save Cialis from 'overly broad' patent claims https://t.co/2rBBlgNDID

— FiercePharma (@FiercePharma) July 9, 2019

https://t.co/sxLYhMpxvg – #Clinical #Catch–#up for June 10-14
https://t.co/XYnsCW41Fh #Sanofi #Lilly #ProventionBio #Eisai #Novartis #Genentech #Savara #BluebirdBio #Janssen #Hutchison #China #Meditech

— GESDAT GmbH (@GESDAT) June 18, 2019

Global Prostate Cancer Therapeutics Market 2026 – Sanofi, Takeda, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Ipsenhttps://t.co/MqR8Y7rxmL #news #pharma #pharmiweb

— Pharma News (@pharminews) June 23, 2020

Medicine Fact's:
FEBUXOSTAT

Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe pic.twitter.com/iL1QiQyFES

— PharmahubNG (@pharmahub_NG) April 23, 2020

https://twitter.com/debasisdas/status/1191697468997505025

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview & Product Profiles 2019 – https://t.co/8vPVgQlQhj https://t.co/QBZCpYtRTH

— Pharmacutical Daily (@PharmacDaily) June 26, 2019

#Ipsen joins @Arixbioscience’s growing pool of pharma partners #biotech #pharma #biopharma #biotechnology #VC #venturecapital #partnerships #EuroBiotech #France #UK #Fosun #Takeda #UCB $IPN $ARIX https://t.co/548ySCuIyC via @FierceBiotech

— Kara Jill Stancell (@kjilly) February 21, 2018

#Japanese #cancer Japanese regulators grant additional approval for the sale of Ipsen's rare cancer drug in Japan https://t.co/pmEsO6Mcov pic.twitter.com/MDv7v96yVV

— PharmaSources.com (@Pharmachina365) July 5, 2017

#efpbarca #medaffairs Ipsen, Eisai, and Astellas on why communicating data to external stakeholders is essential. Find out more here: https://t.co/6p0SXN2R3C pic.twitter.com/o4UdkJxsR8

— The Pharmaceutical Marketing Group (@PharmaMKTnet) October 24, 2018

https://twitter.com/Servier/status/1275363363812450305
https://twitter.com/Servier/status/1273889368801935360
https://twitter.com/Servier/status/1270038222144495616
https://twitter.com/ServierCDMO/status/987605428904366080

Onivyde Now Available in Japan: Servier/Yakult Nihon Servier and Yakult Honsha rolled out its cancer agent Onivyde (liposomal irinotecan) in Japan … https://t.co/h0pZ4komgH

— MEDWAVE (@medinfoa2z) June 2, 2020

Yakult to Promote Servier’s Anticancer Agent Liposomal Irinotecan in Japan Yakult Honsha and Nihon Servier, the Japan unit of the France-based Servier Group, have entered into… https://t.co/IuNVzWp4wK

— MEDWAVE (@medinfoa2z) October 9, 2019

https://twitter.com/conkers3/status/986959011038879744

Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one https://t.co/ie1viNsPi6 pic.twitter.com/VVjxrD1Jz3

— Endpoints News (@endpts) April 16, 2018

Shire's oncology exit weighs on potential Takeda bid: Shire plc is backing out of cancer drugs, announcing Monday the sale of its oncology business to French pharma Servier S.A.S. for $2.4 billion in cash. https://t.co/6TcuucnAtl

— cafepharma (@cafepharma) April 17, 2018

Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles https://t.co/YexpoARs1k pic.twitter.com/yASy7SXm3Z

— Reuters (@Reuters) April 16, 2018

For those interested in the life sciences sector: Shire will be selling its oncology business to French company Servier for $2.4 billion — could this move prevent Japan's Takeda from making a takeover bid for Shire? https://t.co/fQJ2NzF4lA #lifesciences pic.twitter.com/In5rrSyKRn

— Chambers Associate (@ChambersAssoc) April 16, 2018

$SHPG announced today that they are willing to sell their oncology business to France's Servier SAS for about $2.4 billion, as it continues to discuss another possible $50 billion takeover by Japan's Takeda Pharmaceutical. https://t.co/UKVAuq8fLE pic.twitter.com/FG6cAk2Gle

— Stock Analyst (@USCheapStocks) April 16, 2018

#Japan @Takeda @Reuters @London @Japan @TakedaPharmaceutical @Servier #Cancer #DYK #AllThingsCancer #CancerMoonShot #EndCancer #FindACure #CancerTodayMag #JoinTheFight #CancerResearch https://t.co/lN4EPjg7gQ
Shire sells cancer drugs to #Servier as #Takeda circles

— Ken Nitz (@knitz22) April 16, 2018

Three days until our West Coast Conference in L.A.! If you haven’t registered yet, there’s still time: https://t.co/Q2741YJGmW Huge thanks to our sponsors: @genentech @hsn @pfizerinc @pgbeauty @qvc @novartis, Eisai, @LLSusa & @Servier ✨ #bethebossovercancer #CACwestcoast pic.twitter.com/bSd4KXpTUy

— Cancer and Careers (@CancerAndCareer) October 23, 2019

Pharmaceutical Formulations for Asia from Japan
Pierre Fabre, a leading French manufacturer of pharmaceutical products and dermatological cosmetics, opened its Asia Innovation Center PFDC in Japan in 2014 and began formulations activities … https://t.co/6KNKghWWMd pic.twitter.com/Syp79UHJiW

— HC_Tokyo (@nadoCb) February 3, 2018

Articles about Japan after Prime Minister’s resignation announcement through today 首相辞意表明後今日までの日本関連英文記事

All the below tweets are in English.

標記につき取り急ぎ貼っておきます。

Japan's Suga says coronavirus a top priority, to stay on Abe policy course https://t.co/KH014DRWAv pic.twitter.com/4qduiKwGMc

— Reuters (@Reuters) September 8, 2020

Japan to spend $6.3 billion from emergency reserve for coronavirus vaccines https://t.co/FQOL8jfScS pic.twitter.com/d0szcvoMhm

— Reuters (@Reuters) September 8, 2020

Japan's Suga signals chance of calling snap election: Asahi https://t.co/FNnJVT5bRf pic.twitter.com/HysayXM3Fx

— Reuters (@Reuters) September 8, 2020

Senior Japan ruling party member suggests early election: media https://t.co/VWOXatSa1Q pic.twitter.com/c2pMrevZLd

— Reuters (@Reuters) September 6, 2020

Japan's Suga jumps in popularity, tops favourability poll for next PM https://t.co/GrPwSAlYxI pic.twitter.com/qpyQBhiAhV

— Reuters (@Reuters) September 4, 2020

Backroom deals, old-school politics help rise of Japan's likely new premier https://t.co/vmEpeiK4uo pic.twitter.com/kgPBXJYtJZ

— Reuters (@Reuters) September 3, 2020

Japan defence chief Kono expects to be prime minister one day, but backs Suga to succeed Abe https://t.co/DD2zcP0akQ pic.twitter.com/UtWRxXKs1T

— Reuters (@Reuters) September 3, 2020

Japan’s Chief Cabinet Secretary Yoshihide Suga has officially declared he will run for the leadership of the ruling party, making him the top contender to take over from Prime Minister Shinzo Abe https://t.co/TzpKpHbjBC pic.twitter.com/jORgubKuHm

— Reuters (@Reuters) September 3, 2020

Factbox: A stern enforcer who does 100 sit-ups daily – some facts about Japan's Suga https://t.co/pcTXr9DwNM pic.twitter.com/jEb9W3UV5k

— Reuters (@Reuters) September 3, 2020

UK/Japan trade deal good for consumers, companies, Johnson tells Abe https://t.co/TNjnqVIUQH pic.twitter.com/WXRIUdjXun

— Reuters (@Reuters) September 2, 2020

Japan's Suga says to brief on party leadership race, in signal he intends to run https://t.co/6WRex12uln pic.twitter.com/5bClAPgbrY

— Reuters (@Reuters) September 2, 2020

Suga as Japan's next premier may be tough partner for Bank of Japan https://t.co/sdxZ95GQMq pic.twitter.com/Gqtqh5tZnj

— Reuters (@Reuters) September 2, 2020

Japan's Suga expected to announce candidacy for PM race https://t.co/73AeSksV6K pic.twitter.com/krK0Mmsae7

— Reuters (@Reuters) September 2, 2020

Yoshihide Suga, a long-time lieutenant of outgoing Japanese Prime Minister Shinzo Abe is seen as a top contender in the PM race after he won the backing of the ruling party's largest faction https://t.co/Hgl9w7shZi pic.twitter.com/eyRQRDo5Jx

— Reuters (@Reuters) September 1, 2020

Japan's next premier to find pandemic eroding job market gains made by 'Abenomics' https://t.co/0L8X5in763 pic.twitter.com/gNn0nIHzzi

— Reuters (@Reuters) September 1, 2020

Suga seen top contender in Japan PM race as ruling party plans slimmed-down vote https://t.co/wVg1hKtAud pic.twitter.com/IXQ4q2lUwz

— Reuters (@Reuters) September 1, 2020

Japan former foreign minister Kishida announces candidacy to succeed PM Abe https://t.co/KAJ37IIfMb pic.twitter.com/qMr56YBcHi

— Reuters (@Reuters) September 1, 2020

Japan's Motegi: to decide whether to run in party leadership race in a day https://t.co/8lZGGf2BoK pic.twitter.com/o5VXzZLFuc

— Reuters (@Reuters) September 1, 2020

Yoshihide Suga, Japan’s chief cabinet secretary and a long-time lieutenant of outgoing Prime Minister Shinzo Abe, won the backing of the largest faction of the ruling party to become its next leader, according to public broadcaster NHK https://t.co/CLTrfpHfLq pic.twitter.com/vwmsuBxYPr

— Reuters (@Reuters) September 1, 2020

Japan LDP execs agree on simplified format to pick next PM: Nikai https://t.co/JBSiprHkGl pic.twitter.com/MKUrzwGUYf

— Reuters (@Reuters) September 1, 2020

Japan Defence Minister Kono says still undecided on run for ruling party leadership https://t.co/RIOCsS4eR8 pic.twitter.com/mL7SYNzqWs

— Reuters (@Reuters) September 1, 2020

Ex-Japan defence chief mum on whether he'll join PM race https://t.co/xL8Vv4OMDZ pic.twitter.com/UJZnho5erd

— Reuters (@Reuters) August 31, 2020

How does Abenomics stack up? Reuters asked the experts https://t.co/rk2GIdauOE pic.twitter.com/7uwEQXu575

— Reuters (@Reuters) August 31, 2020

Japan's ruling party to hold September 14 leadership vote; four possible candidates for PM https://t.co/vnOX7Hld4q pic.twitter.com/OyLahCgjeL

— Reuters (@Reuters) August 31, 2020

Japan's PM candidate Kishida cautious about cutting sales tax https://t.co/NX1GzOZzii pic.twitter.com/MF5DaqtiwV

— Reuters (@Reuters) August 31, 2020

Ex-defence minister Ishiba is people's choice for next Japan PM: polls https://t.co/vz2wwRC27L pic.twitter.com/FDUz78EpgK

— Reuters (@Reuters) August 31, 2020

In his first race for office, Japan's likely next prime minister knocked on 30,000 doors and wore out six pairs of shoes https://t.co/9u4C78fBxC

— The Wall Street Journal (@WSJ) September 7, 2020

By the time Prime Minister Shinzo Abe announced his resignation last week, he had presided over a remarkable and unexpected opening up of Japan to the world https://t.co/Q8QCHMDkLk

— The Wall Street Journal (@WSJ) September 3, 2020

Japan’s next leader will face a question many other countries are now grappling with because of the coronavirus pandemic: How much can central banks do to pull economies out of a deep malaise? https://t.co/ijydChWQXa

— The Wall Street Journal (@WSJ) August 31, 2020

Prime Minister Shinzo Abe’s two stints in office reshaped modern Japan https://t.co/VQbZJ35bZD

— The Wall Street Journal (@WSJ) August 29, 2020

Whoever Japan's Liberal Democratic Party elects as its leader, probably within the next week, will almost certainly become the country's next prime minister. But it isn’t clear who that will be. https://t.co/1vYWIME0Wb

— The New York Times (@nytimes) August 30, 2020

News Analysis: Whoever Japan's next leader is will have to face the coronavirus, a tanking economy, an aggressive China, a postponed Olympics and a U.S. election. And that's just the start. https://t.co/dHglv1aM1b

— The New York Times (@nytimes) August 30, 2020

Japan’s "Mr. Fixit," Yoshihide Suga, set to succeed Shinzo Abe as leader https://t.co/HaoZIM3NBs

— The Washington Post (@washingtonpost) September 1, 2020

Opinion: Shinzo Abe decided to go all out on Donald Trump. He’s probably regretting it now. https://t.co/u2VEjVoz9D

— The Washington Post (@washingtonpost) August 30, 2020

What does #Abe Shinzo’s resignation mean for Japan’s future? The post-Abe calculus is aggravated by Japan’s domestic political flux, a congested electoral calendar and unpromising economic and geopolitical environments, writes @RobertAlanWard | https://t.co/EelZfg6zG6 pic.twitter.com/5RHLVs3odh

— IISS News (@IISS_org) August 28, 2020

'The old paradigm of the US-Japan alliance is that Japan wears the "shield" and hosts the "sword". But that paradigm has been breaking down for many years,' says @graham_euan, Senior Fellow for Asia-Pacific Security | @firstpost https://t.co/56fnzqDI3B

— IISS News (@IISS_org) August 17, 2020

China’s rise as a geo-economic power has driven the Abe administration to reshape its foreign-policy bureaucracy and recalibrate its approach to economic statecraft – read more in the Strategic Comment | https://t.co/eVGsEQOXkB pic.twitter.com/3U0FLlthPA

— IISS News (@IISS_org) August 24, 2020

'Chinese activities in the waters around the Senkaku/Diaoyu islands have undergone a significant change over the past few months. This is a potentially dangerous development for Sino–Japanese relations.'
New Newsbrief from Dr Alessio Patalano.https://t.co/8ysPOtONLs pic.twitter.com/T0MwNK9M0h

— RUSI (@RUSI_org) August 22, 2020

https://twitter.com/rielcano/status/1297115296977817602

“China has a lot of cards to play, so the policies of the next administration—again, regardless of who is president—will have to respond to Beijing.”

Insights from @JJCarafano on the future of Asia policy via @jljzen: https://t.co/Pqn3BYeD0F

— Heritage Foundation (@Heritage) August 21, 2020

Yoshihide Suga, Japan's Chief Cabinet Secretary and a longtime loyal assistant of outgoing Prime Minister Shinzo Abe, has emerged as a favourite to succeed him in an upcoming internal party vote https://t.co/n1zNdzRRgy

— The Sydney Morning Herald (@smh) September 2, 2020

Japan's Prime Minister Shinzo Abe has been forced to resign due to ongoing poor health.https://t.co/OmmN6lmxpi

— nzherald (@nzherald) August 28, 2020

Five venerable Japanese companies were sitting in the bargain bin in plain sight. It took a 90-year-old Warren Buffett to scoop them up. https://t.co/LmocOAatM2

— The Wall Street Journal (@WSJ) September 5, 2020

Japanese conglomerate SoftBank fueled the recent stock market rally by buying options tied to billions of dollars worth of individual tech stocks, people familiar with the matter say https://t.co/5qJeeaemXS

— The Wall Street Journal (@WSJ) September 4, 2020

SoftBank value slumps as investors fear it may be the 'Nasdaq whale' https://t.co/TY75uJPCcI

— The Guardian (@guardian) September 7, 2020

Warren Buffett’s Berkshire Hathaway took stakes in five Japanese trading companies, expanding its reach abroad https://t.co/QJkPjn15ou pic.twitter.com/Dsc5vFQlUO

— Stuart Wallace (@StuartLWallace) August 31, 2020

BREAKING: Warren Buffett's Berkshire Hathaway buys stakes in Japan's five leading trading companies https://t.co/9RzX6prgmH

— CNBC Now (@CNBCnow) August 30, 2020

https://twitter.com/Forbes_MENA_/status/1300379518184689664

Berkshire Hathaway invests $6 billion in five Japanese companies https://t.co/GPzyETMsvI pic.twitter.com/JWGLP2GK5D

— New York Post (@nypost) August 31, 2020

The Japanese Coast Guard was searching for a livestock ship that capsized with dozens of crew members and nearly 6,000 cows aboard, after a typhoon barreled through East Asia on Thursday https://t.co/49zbjiV6Nx

— The New York Times (@nytimes) September 3, 2020

Japan's convenience store industry is under scrutiny after allegations that companies used strong-arm tactics to force franchisees to maintain 24-7 operations, leading overworked owners to collapse from exhaustion https://t.co/Jw6JgV5NZo

— The New York Times (@nytimes) September 3, 2020

Naomi Osaka brought seven face masks to the U.S. Open, each one honoring a victim of violence https://t.co/R8DtfLqODc

— The Washington Post (@washingtonpost) September 1, 2020

Japan coastguard finds second person in search for crew of capsized cattle ship https://t.co/jIvgQsXsbt

— The Guardian (@guardian) September 4, 2020

Typhoon Maysak: ship with 43 crew and nearly 6,000 cattle missing off Japan https://t.co/gU83kN9HXq

— The Guardian (@guardian) September 3, 2020

#BREAKING The second person rescued by Japanese coastguard has died. https://t.co/YrzrVGD9Sg pic.twitter.com/G3vTOgyyKc

— nzherald (@nzherald) September 4, 2020

Japan's Sumitomo sells all of its stake in U.S. Marcellus shale gas project https://t.co/LggosGUiNQ pic.twitter.com/CvYxUJ9YpS

— Reuters (@Reuters) September 8, 2020

Japan's economy sank deeper into its worst post-war contraction in the second quarter as the coronavirus jolted businesses, intensifying the challenge for the country's new leader https://t.co/eeC1TtV3Ku pic.twitter.com/72RDS5h49f

— Reuters (@Reuters) September 8, 2020

Japan real wages decline for fifth month in July as pandemic woes persist https://t.co/ujb8GDH0nK pic.twitter.com/TjeIxXD0hp

— Reuters (@Reuters) September 8, 2020

Japan's July household spending falls 7.6% year-on-year https://t.co/05HkfoDhDx pic.twitter.com/ncXaEsJqIB

— Reuters (@Reuters) September 8, 2020

Japan's Nishimura says rising income to underpin consumption https://t.co/5qJ2SSC5jr pic.twitter.com/1zwxo0quDi

— Reuters (@Reuters) September 8, 2020

Japan's second-quarter GDP revised down to annualised 28.1% contraction https://t.co/ciKbcDVRdG pic.twitter.com/sM3nX7nGwH

— Reuters (@Reuters) September 8, 2020

Japan real wages decline for fifth month in July as pandemic woes persist https://t.co/oLovkMNqCE pic.twitter.com/2mRvUgLL4R

— Reuters (@Reuters) September 8, 2020

Japan says it offered Mauritius 'unprecedented' support, including financial https://t.co/cDucu3Tijm pic.twitter.com/rcaUDTSeb5

— Reuters (@Reuters) September 7, 2020

Renault to develop, build next-generation Nissan Micra: report https://t.co/IIW1D4HZMe pic.twitter.com/w1AmP2J46G

— Reuters (@Reuters) September 7, 2020

The Fed’s landmark shift to a more tolerant stance on inflation will be a drag on the dollar for years and will raise hard questions about the role of central banking, challenging policymakers from Frankfurt to Tokyo https://t.co/PzzcVF2WEa pic.twitter.com/bwU58rbiqg

— Reuters (@Reuters) September 7, 2020

Japanese government exposed to 40% of $6.7 billion Nissan loans: sources https://t.co/s74k5ibgXO pic.twitter.com/3TL6RnDHc1

— Reuters (@Reuters) September 7, 2020

Death knell sounds for some of Japan's oldest department stores https://t.co/XkVMHEJQop pic.twitter.com/r2UTHa6EXI

— Reuters (@Reuters) September 7, 2020

Amazon Japan submits improvement plan to regulators: Asahi https://t.co/FchYZNr0i7 pic.twitter.com/lhstyjzaMm

— Reuters (@Reuters) September 4, 2020

Japan's government is considering further assistance to help Mauritius deal with a major oil spill after a Japanese-owned boat struck a coral reef pic.twitter.com/LELPYdmqgR

— Reuters (@Reuters) September 3, 2020

Japan's coastguard rescued one person while searching for a cargo ship carrying nearly 6,000 cattle and dozens of crew members that went missing in the East China Sea https://t.co/An8nLUfi4a pic.twitter.com/KZekO8cFJi

— Reuters (@Reuters) September 3, 2020

BOJ's Kataoka urges bolder easing to battle deflation risk https://t.co/2LxzPSU2SE pic.twitter.com/UWB9FJqFg5

— Reuters (@Reuters) September 3, 2020

Japan's August service sector activity worsens as pandemic stymies recovery https://t.co/wHHpqn8nBN pic.twitter.com/maiuZJwI0y

— Reuters (@Reuters) September 3, 2020

Japan looks to AI as coronavirus challenges go-and-see quality control mantra https://t.co/INQIGWyG16 pic.twitter.com/4oSruhvBft

— Reuters (@Reuters) August 31, 2020

As fintech upends banking, Japan regulator expects more cross-boundary tie-ups https://t.co/nhVjPT8MC3 pic.twitter.com/WlsEaJuhsB

— Reuters (@Reuters) August 31, 2020

Japan July retail sales fall 2.8% year-on-year, government data shows https://t.co/HlH0tdU2Sr pic.twitter.com/3bQ5tUxewH

— Reuters (@Reuters) August 31, 2020

From @Breakingviews: @johnsfoley explains why Warren Buffet is going big in Japan pic.twitter.com/tA2jBVqc13

— Reuters (@Reuters) September 1, 2020

Nippon Steel to seek overseas M&As, but not in Japan: president https://t.co/lKCoLkWAui pic.twitter.com/xgb2PQVlu1

— Reuters (@Reuters) September 1, 2020

Warren Buffett looks to Japan, takes 5% stakes in five biggest trading firms https://t.co/CErrl7nR2E pic.twitter.com/3wA9AUhtS8

— Reuters (@Reuters) August 31, 2020

Japanese PM Shinzo Abe says he's stepping down because of a chronic health problem https://t.co/0p5wm1yElD

— POLITICO (@politico) August 29, 2020

Japanese Prime Minister Shinzo Abe has expressed his intention to step down, citing his declining health, according to Japan’s NHK television and other media https://t.co/0p5wm1yElD

— POLITICO (@politico) August 28, 2020

Science and Technology 科学技術 Vol.9 ／ #Coronavirus #コロナウイルス Vol.11

All the below links and tweets are in English.

ツイッター検索で出て来た broadband と日本に関連するツイート（The below are broadband-related Tweets which happened to come out of Twitter search on Sep 6. They must be just a part of all the posted Tweets as usual.）

The HAPS #HAWK30 is a next generation #Solar powered #UAS >>> @aerovironment and @SoftBank via @globaliqx >>> #Broadband #UAV #Drones #IoT #5G #Robotics #defstar5 #Aerospace >>> https://t.co/9dlZzzaKUz pic.twitter.com/qXF8hZ0cvU

— Mike Quindazzi ✨ (@MikeQuindazzi) December 19, 2019

City interview with Adrian Steckel, the boss of SoftBank-backed British satellite broadband firm OneWeb. He tells me the plans is to float in 24-36 months when it has launched all its satellites https://t.co/5bfuSmIj3c

— Jamie Nimmo (@JamieNimmo63) August 11, 2019

SoftBank is investing $125M in rural balloon broadband startup. pic.twitter.com/vMkawziQDX

— Digital Trends (@DigitalTrends) April 29, 2019

NTT Docomo’s bullet train mmWave 5G test speeds past 1Gbps https://t.co/LSWB46UTwp #Telecom #Networks #Telco #Cloud #Telecoms #Mobile #Wireless #IIoT #Broadband #IoT #EdgeComputing #5G @NTTDocomoNews @NTTDATAServices #japan

— Evan Kirstel #RemoteWork (@EvanKirstel) September 30, 2019

Docomo Offers 1Gbit/s Services to Train Going 283km/h Using 5G https://t.co/r2oDLyhnql via @Light_Reading #Telecom #Networks #Telco #Cloud #Telecoms #Mobile #Wireless #IIoT #Broadband #IoT #EdgeComputing #5G #japan @GlobalNTT @NTTDATAServices pic.twitter.com/DszjUnlXSP

— Evan Kirstel #RemoteWork (@EvanKirstel) October 1, 2019

Tokyo power company orchestrates 5G infrastructure sharing https://t.co/oJ1MCtD79Q #5G #APAC #BusinessModels #mmWave #Regulation #Research #SmartCities #Japan #Networks #Telecoms pic.twitter.com/bfdKQ9hQYT

— TelecomTV (@TelecomTV) March 19, 2019

KDDI is deploying https://t.co/TeRdCkxVRJ in Japan to tackle its huge MDU opportunity https://t.co/vxQywU8Ves #APAC #Broadband #Telecoms #Gfast #Fibre pic.twitter.com/WJnfp8FQYu

— TelecomTV (@TelecomTV) February 4, 2019

KDDI deploys Nokia gigabit https://t.co/vQJiRQTOpO solution to bring new services to its high-speed internet 'au Hikari' customers in Japan | Nokia https://t.co/RfBdVqtHiq #gfast #broadband

— Teresa Mastrangelo #broadband #smartcities (@broadbandtrends) February 4, 2019

KDDI takes conventional approach in land of new 5G architectures…https://t.co/34uaiPGsOM #wireless #5G #wifi #cellular #operators #spectrum #RAN #broadband #iot #rethinktechnology #iot @KDDI_Research @NTTDocomoNews @Rakuten @SoftBank @ericsson @nokia pic.twitter.com/cMpl3iWGNs

— Wireless Watch (@RethinkWireless) October 9, 2019

Gfast Brings High-Speed Broadband to KDDI MDU Customers https://t.co/S6XWP92djM

— Broadband World News (@BroadbandWN) February 5, 2019

BBWN Bites: Verizon, Spectrum Top Netflix Tier-One Speed Rankings
Also today, Boris's broadband goal gets no love in Parliament, Roku delivers for Apple fans, Tubi targets UK and kids, Rakuten TV brings freebie ad-supported service, Chile seeks tenders forhttps://t.co/UgMkqUnWTV

— Broadband World News (@BroadbandWN) October 15, 2019

Network disaggregation saves Rakuten up to 60% on their new 5G network – we've seen the same on fixed broadband networks. Time to goodbye to monolithic network hardware?#networkdisaggregation https://t.co/A7YpZPAfqA

— RtBrick (@rtbricknet) August 26, 2020

On this episode of Quick Talk, a TM Forum podcast, we discuss Rakuten Mobile’s #5G deployment delay due to #COVID-19, the impact of US-China relations on @Huawei and taking mobile broadband pricing for granted. Listen now: https://t.co/v26HjWItYF cc: @Rakuten_Mobile

— TM Forum (@tmforumorg) May 28, 2020

Rakuten invests in "AST & Science" space venture to extend future mobile coverage to people and devices across the planet, with the first mobile broadband network that will be broadcast from space.https://t.co/MnD4QDPFlC

— Rakuten Today (@RakutenToday) March 5, 2020

AST & Science raises $110M Series B led by Rakuten and Vodafone to build a broadband network via a constellation of satellites that link directly to smartphones (@chenry_sn / SpaceNews)https://t.co/76BiThEvto https://t.co/IQqsJFzkPi

— Techmeme (@Techmeme) March 8, 2020

Rakuten and Vodafone are the lead investors in a just-announced space-based cellular broadband network called SpaceMobile from AST & Science. https://t.co/4eLDMCPcWd

— Via Satellite (@Via_Satellite) March 4, 2020

We are proud to partner with Rakuten to demonstrate #5G's capabilities for enhanced mobile broadband and industry 4.0 applications: https://t.co/AXXCWwLUBV pic.twitter.com/peFzI18vCI

— Nokia for CSPs (@nokianetworks) October 2, 2018

BBWN Bites: Verizon, Spectrum Top Netflix Tier-One Speed Rankings
Also today, Boris's broadband goal gets no love in Parliament, Roku delivers for Apple fans, Tubi targets UK and kids, Rakuten TV brings freebie ad-supported service, Chile seeks tenders forhttps://t.co/ULUbf2u66W

— Broadband World Forum (@BBWorldForum) October 15, 2019

Gfast Brings High-Speed Broadband to KDDI MDU Customers
Japanese provider KDDI will use Nokia's Gfast solution to bring speeds of up to 830 Mbit/s to city dwellers.https://t.co/Dw1zkJ7Pbq

— Broadband World Forum (@BBWorldForum) February 5, 2019

KDDI and Nokia boost Japanese broadband speeds by 800% https://t.co/DBrYmtCE8e pic.twitter.com/4JZsUnlAXf

— Connected Britain (@ConnBritain) February 4, 2019

For example – here is Masa talking about putting off short-term profits to gain long-term market share. Which he did in the Japanese broadband market in the early 2000s and the Japanese wireless market in the late 2000s.https://t.co/NRanIGHnc9

— Masa Capital (@MasaSonCap) June 9, 2020

Merger delays and teething troubles pull back Sprint and TMO 5G roll-outs…https://t.co/vzN3F8wZZ9 #wireless #5G #wifi #cellular #operators #spectrum #RAN #broadband #rethinktechnology @sprint @TMobile @Rakuten @ATT @verizon pic.twitter.com/YswQgCkWcF

— Wireless Watch (@RethinkWireless) September 3, 2019

https://twitter.com/dinoflore/status/1100105372709343234

Nokia and KDDI trial 5G with AirScale radio for wireless ultra-broadband in megacities https://t.co/2CG7axmiFv pic.twitter.com/SrxN7i5DiH

— Nokia News (@nokianews) May 12, 2017

Canada’s telecom watchdog to work with Japan to combat spamhttps://t.co/SUVLncU8zJ pic.twitter.com/vGGfayxUV0

— MobileSyrup (@MobileSyrup) January 6, 2018

.@SoftBank held talks with @BSNLCorporate for leasing out broadband bandwidth from #OneWeb's low earth orbit communication satellites to disrupt the telecom tech landscape in India with low latency Internet and voice services https://t.co/lRPEVPV2eP

— Economic Times (@EconomicTimes) April 27, 2018

SoftBank has agreed to invest around $500 million more in satellite broadband provider OneWebhttps://t.co/T2689aGNIU

— The Wall Street Journal (@WSJ) December 12, 2017

KDDI's broadband deal seeks clout with households https://t.co/OOnmpD8isg pic.twitter.com/DyhYiMtgBI

— Nikkei Asian Review (@NAR) December 8, 2016

Softbank/Sprint CEO Masa Son uses Comcast, and isn't happy with his broadband speeds. #codecon pic.twitter.com/dphPmctFoX

— Brad Molen (@phonewisdom) May 28, 2014

.@SoftBank is unlikely to keep supporting @OneWeb, a source familiar with the situation said, as an activist investor agitates for change at the Japanese internet giant amid rumours that its LEO broadband holding is mulling bankruptcy. https://t.co/CLIYbv9FiY pic.twitter.com/IF1ELWmx9c

— Connectivity Business (@connectivity_b) March 26, 2020

Japan's fussy food shoppers finally go online amid pandemic | The Japan Times. The notable thing here is the comment from a Japanese journalist that Britain is the odd man out with broadband. Even on Japanese islands you get broadband! https://t.co/2pGdBXam0Y

— Maurice is not a nice man (@colonelmuppet) July 5, 2020

Half of UK consumers struggled with broadband speeds — NTT DATA @informationage #data #analytics https://t.co/bOf3GLGplT

— Eric Axelrod (@axelrod_eric) August 29, 2020

Only 8-10% of premises in the UK are connected to full-fibre broadband. It's 97% in Japan.

8 in 10 of us experienced internet problems in the last year.

So we'll make the very fastest full-fibre broadband free to everybody, in every home in our country.

That's real change.

— Jeremy Corbyn (@jeremycorbyn) November 14, 2019

Why do we need action on Broadband? Try this. The UK has low levels of full-fibre broadband internet, at just 7%. In comparison, Portugal has 89%, Japan 97% and South Korea 99%. Now do you see why existing solutions can’t work? If they could have they already would have.

— Richard Murphy (@RichardJMurphy) November 15, 2019

Like Lab has said *so* many times, 95% of people won't have their taxes raised

UK has one of the worst rates of broadband- 7%. Portugal 89%, Japan 97% & S. Korea 99% #freebroadband would boost productivity by £59bill, bring 1/2mill ppl into the work & boost rural economies https://t.co/u5Nwq9rp2O

— antonia jennings (@tweetingantonia) November 15, 2019

Actual Wow!

The BBC describe Labour's plan to hook everyone up to Broadband (like Japan & South Korea do) as Communism

This really is a new level of bias by the BBC – even for their standards. pic.twitter.com/VRCxdCJbx6

— The Pileus #RefugeesWelcome (@thepileus) November 15, 2019

when I was in rural Japan in 2005, I could get 150mbps broadband because the government had built it. In 2019 my parents in rural Suffolk can only get 4mpbs broadband because private enterprise has failed to build it.

— Jonathan Paige (@johnnypaige) November 14, 2019

Average monthly cost of broadband:

Russia: $10
Poland $18
France: $31
Mexico: $33
Germany: $37
Japan: $37
Britain: $40
China: $41
Chile: $46
Denmark: $51
Australia: $53
Sweden: $56
Canada: $58
.
.
.
United States: $68

This is why monopolies are bad. https://t.co/3zJ7RDrau9

— Public Citizen (@Public_Citizen) November 11, 2019

Even our internet is neo-Liberal…

Aust is coming last in affordability rankings for entry-level broadband services.

Of developed (OECD) nations, Aust is at 36th. Japan is first, US 6th, UK 7th, New Zealand 21st ⁦@QuentinDempster⁩ #auspol #nbn https://t.co/yGouPHfeCS

— Denise Shrivell – North Sydney for an Independent (@deniseshrivell) August 27, 2019

Holy shit, New Zealand is ahead of Japan in Speedtest's fixed broadband speed global index https://t.co/2ec6JHO38L pic.twitter.com/YZoFeXuv4E

— Andrew Sykes (@Interlime) September 15, 2018

By the end of 2022, China, Japan, South Korea, Canada and the U.K. will have nearly 2X the amount of mid-band spectrum as the U.S. Our latest report outlines near-term opportunities for the U.S. to close the mid-band spectrum deficit: https://t.co/oiOx1zaXBJ pic.twitter.com/wkk4YR2Qd0

— CTIA (@CTIA) July 11, 2020

Military Cyber Affairs reports Chinese government used China Telecom to divert Internet traffic between 2015 and 2017. The report named 4 specific routes: Canada to South Korea, US to Italy, Scandinavia to Japan, and Italy to Thailand. https://t.co/v0EGoV4YkQ pic.twitter.com/pEMmfAGoGZ

— Laurent Perche (@Laurent_Perche) November 9, 2018

Canada can learn from initiatives in Japan & Australia on broadband use & adoption: https://t.co/5LCZx89zPs #DPSummit17 pic.twitter.com/zUPPjjuGPe

— Canadian Chamber of Commerce (@CdnChamberofCom) February 15, 2017

"5G war" as distraction from universal fiber to the prem #FTTP: "I’ve been hearing about the 5G war for a few years now and I still don’t know what it means…If there is now a 5G war, then why hasn’t there been a fiber-to-the-home war?" https://t.co/uV7MxFSZuh

— U.S. Telecom Infrastructure Crisis (@EldoTelecom) December 27, 2019

After US, Japan, Austalia now its time for Germany to stop Huawei from getting into their critical telecom infrastructure. It is really needed #5G #IoTSecurity https://t.co/Xp4Fx1pB0g

— Contra (@BannaGordhan) November 15, 2018

The British government decided to remove Huawei equipment from its 5G networks by the end of 2027. Two days later, they ask Japan to help build its 5G infrastructures. More on #InsideTelecom.#telecom #tech #5g #Britain #uk #japan #network https://t.co/Gi2yJfJXmo

— InsideTelecom (@insidetelecom_) July 27, 2020

Spot on from @TomTugendhat. “Every general wants to pick the battlefield and divide their enemy…Continuing to allow Huawei into the UK’s networks, triggering the reaction Washington has just ordered, that’s exactly what Beijing is succeeding in doing.” https://t.co/uXLgqs1YOX

— Owen Paterson (@OwenPaterson) May 6, 2020

The US is working with Australia & Japan to stop Chinese telecoms giant Huawei from building a major internet infrastructure project in #PNG. It's the latest sign of international efforts to curb China’s broadening influence in the Pacific
https://t.co/2mGJSQGqaH

— Keith Jackson AM (@PNGAttitude) September 28, 2018

The U.S. scrutiny has led governments in Australia, Britain, Canada, Germany, Poland and Japan to all examine their telecom supply chain, as well,while Australia and New Zealand have already restricted Huawei's potential involvement in their coming 5G net https://t.co/aXsGNktiVk

— jasonleeramsey (@jasonleeramsey) January 26, 2019

Ask the Japanese about FTTP #nbn whilst your there, you might learn something about not wasting $20 billion on a copper lemon #auspol #ausbiz #telecom #gennbn #broadband https://t.co/iwZ7O8jic8

— Mark A Gregory (@_markagregory) January 18, 2018

World 世界情勢等 Vol.6

All the below links are in English.

取り急ぎ以下貼っておきます。

World Vol.40
World Vol.39
World Vol.38
World Vol.37
World Vol.36
World Vol.35
World Vol.34
World Vol.33
World Vol.32
World Vol.31